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ABSTRACT 
 
 
The post-translational conjugation or deconjugation of proteins by ubiquitin (Ub) or 
ubiquitin-like molecules (UbLs: e.g. SUMO, NEDD8, ISG15) has emerged as a major 
regulatory mechanism of various cellular activities. The controlled processes include protein 
transcription, translation, trafficking and degradation, signal transduction, replication and 
apoptosis. All modifier get covalently linked to their substrates via the cascade activity of 
three enzymes (E1, E2, E3). After execution of the modification mediated signaling, 
deconjuagases, belonging to the class of deubiquitinating enzymes (DUBs) or Ubl-specific 
proteases (ULPs), cleave the modifier of its substrate for possible recycling. Given the central 
role of the conjugation and deconjugation pathway in all aspects of cellular physiology, it is 
understandable that viruses have developed mechanisms to exploit those pathways for their 
own benefit. RNA and DNA viruses express their own E3 ligases or manipulate cellular E3 
ligases to facilitate the modification of mostly cellular proteins, which, in the case of 
ubiquitination, often leads to their degradation. Also several viral encoded DUBs or ULPs 
have been described, e.g. facilitating the suppression of ubiquitination and ISGylation 
mediated antiviral effects. 
 
Epstein-Barr virus (EBV) is a large double-stranded DNA tumor virus encoding ∼100 open 
reading frames (ORFs). EBV belongs to the human herpes virus (HHV) family. The virus 
establishes latent infections in 90% of the human population worldwide and like other 
herpesviruses has a latent and lytic life cycle. EBV is associated with a variety of 
malignancies of lymphoid cells, like Burkitt´s lymphoma and Hodgkin´s lymphoma as also of 
epithelial cells, like nasopharyngeal carcinoma and gastric carcinoma.  
 
The overall aim of this study was to identify and functional characterize EBV encoded 
deconjugases. We developed a bacterial screening assay based on the usage of Ub/Ubl-GFP 
reporter constructs. We screened an EBV-ORFeome library for their activity against Ub-, 
NEDD8-, SUMO-1,-2,-3 and ISG15-GFP reporter. As a result we discovered that the BSLF1- 
and BXLF1-ORF comprised deubiquitinating activity. We were further able to confirm the 
earlier described deubiquitinating function of the BPLF1-ORF. BPLF1 is a large tegumental 
protein, comprising DUB activity in its N-terminus, which was described for all of its HVV-
family homologues. In our screening assay we could also detect that BPLF1-N cleaves the 
NEDD8-GFP reporter with similar efficiency as the Ub-GFP reporter. Following this 
observation we could show that BPLF1-N was able to process Ub- and NEDD8-linked 
functional probes with similar efficiency suggesting equal affinities towards ubiquitinated and 
neddylated substrates. We could show that BPLF1-N binds to and deneddylates cullins, which 
are assembled in cullin-RING ligases (CRLs). This CRL deneddylation facilitated the 
stabilization of their substrates involved in cell cycle regulation. Those accumulated BPLF1-
N controlled CRL substrates were essential for an S-phase like cellular environment and 
endoreduplication in BPLF1-N expressing cells. We further demonstrated that the impact of 
BPLF1-N expression on viral genome replication was dependent on stabilization of the DNA 
licensing factor CDT1. 
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1.  INTRODUCTION 
 
1.1.1  The ubiquitin and ubiquitin-like modification system 
 
The post-translational modification of proteins by Ub (ubiquitin) or UbLs (ubiquitin-like 
molecules: e.g. SUMO, NEDD8, ISG15) has emerged as a major regulatory mechanism of 
various cellular activities. Those controlled processes include protein transcription, 
translation, trafficking and degradation, signal transduction, replication and apoptosis (1, 2, 3, 
4, 5). So far 13 UbLs are described in human. All of them have a size between 8-18 kDa and 
they all show a high secondary structure homology to ubiquitin (2). Conjugation of Ub and 
UbLs to their targets requires the sequential action of three enzymes: a modifier-activating 
enzyme (E1), one of several modifier conjugating enzymes (E2s), and one member of a large 
and diverse group of modifier-target ligases (E3s) that mainly determines target specificity 
(1). This enzyme cascade mediates the conjugation of the C-terminal glycine of Ub or UbL to 
the epsilon-NH2 group of a lysine residue (K) of the target protein. Ub and UbLs are 
produced as precursor proteins (Ub also as a polypeptide), and carboxy-terminal processing 
by specific proteases is required to generate an active modifier. Those specific deconjugating 
enzymes, called DUBs (deubiquitinating enzymes) and ULPs (Ubl-specific proteases), also 
cleave the modifier from its target protein by hydrolyzing the covalent bondage between 
substrate and modifier. The purpose of this reaction is to establish a sufficient pool of free 
Ub/Ubls and to determine certain signaling or functional alteration caused by the modification 
(6). An overview of the ubiquitin and ubiquitin-like modification system with examples for 
the non-proteolytic and proteolytic outcomes are visualized in figure 1. 
 
Figure 1. Ub polypeptides or UbL pro-peptides need to be processed from DUBs or ULPs to make their terminal 
Glycin accessible for conjugation. Via an enzymatic cascade of activating enzyme (E1), conjugating enzyme 
(E2) and substrate ligase (E3) the modifier gets covalently linked to its substrate. This modification can either 
have a non-proteolytic or a proteolytic outcome. After signaling the modifier gets deconjugated from its 
substrate by DUBs or ULPs for possible recycling into the system.  
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1.1.2  Ubiquitin modification 
 
Ubiquitin, a small globular protein composed of 76 amino acids, is highly conserved during 
evolution. The first discovered function of ubiquitin is its involvement in the UPS (ubiquitin-
proteasome system). This pathway is a major intracellular system for protein degradation. The 
connection of at least four K48 linked Ub molecules to a protein serves as localization signal 
to the proteasome where the labeled protein gets degraded (1). This pathway plays a crucial 
role in a wide variety of cellular function, including degradation of damaged or unneeded 
proteins, cellular trafficking, antigen processing, cell cycle regulation and apoptosis (7). Apart 
from the described K48 Ub chain mediated protein degradation several other Ub mediated 
function have been described. Ubiquitin contains seven lysine residues K6, K11, K27, K29, 
K33, K48, and K63. Formation of the ubiquitin chain can occur by linking the ubiquitin 
polymer to any of these lysine residues in homogeneous or mixed form. The length and the 
linkage construction of the created Ub chain determine the faith of the modified 
protein. Apart from modification via K48 Ub chains, monoubiquitination and K63 Ub chain 
conjugation are the best characterised Ub modifications. Many membrane receptors are 
monoubiquitinated, which serves in most cases as endocytosis signal and in many 
circumstances as signal for lysosomal degradation. Also histones are monoubiquitinated, 
which serves as signal for histone-mediated transcriptional regulation. Monoubiquitination 
has also been described to alter sub-cellular location or determine cellular interaction of the 
modified substrate (8, 9). For instance PCNA (proliferating cell nuclear antigen) is a 
homotrimeric replication sliding clamp that encircles DNA and provides a platform to recruit 
other proteins involved in DNA replication and repair. Monoubiquitinated PCNA recruits 
TLS (translation synthesis) polymerases, which display low processivity and reduced fidelity 
allowing DNA lesion bypass, to replace the high-fidelity polymerases. The 
monoubiquitination of PCNA can be further extended to K63-linked polyubiquitin chains. 
This polyubiquitination activates an alternative lesion bypass pathway called template switch, 
which recruits the undamaged strand of the DNA duplex as a template to direct DNA 
synthesis (10). Further described protein-protein interactions mediated via K63-linked 
polyubiquitination are important for kinase signalling activation (e.g. leading to NF-κB 
activation), receptor endocytosis and protein trafficking (11). The best characterized UbL- 
modifier in human are SUMO, NEDD8 and ISG15. 
 
 
1.1.3  SUMO modification 
 
The mammalian SUMO (Small ubiquitin-like modifier) family is comprised of three members 
with described physiological function. SUMOs have a size of about 95 amino acids and 
constitute a highly conserved protein family found in all eukaryotes. SUMO-1 share ∼50% 
sequence identity with SUMO-2 and -3. SUMO-2 and SUMO-3 share ∼95% sequence 
identity. SUMO-2 and -3 are able to form monomeric and heteromeric poly-SUMO chains 
like Ubiquitin. SUMO-1 in contrast, is not able to form poly-SUMO chains but may bind 
covalently to SUMO-2 and -3 conjugated chains and terminate them. Most SUMO-modified 
proteins, which have been characterized in human, are involved in transcription. The 
transcriptional effects of SUMO can be divided into two groups, those that involve PML 
nuclear bodies and those that involve sumoylated transcription factors bound to DNA 
promoters. PML nuclear bodies are matrix-associated domains that recruit an ever-growing 
variety of proteins.  The PML-protein is the key organizer of these domains, which up on 
sumoylation facilitates the formation of PML nuclear bodies, recruiting among others 
transcription factors, which get activated via this association. Sumoylation occurring direct on 
the transcription factor facilitates in most cases transcriptional repression.  
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This occurs either by altering the stability of a DNA bound transcription factor or by the 
recruitment of a transcriptional repressor. In general most sumoylated substrates are localized 
in the nucleus and many of those substrates require their NLS (nuclear localization sequence) 
for sumoylation. The most abundant SUMO-1 conjugate in vertebrate cells is RanGAP1. This 
protein is the GTPase activating protein for the small GTPase Ran, which plays a central role 
in nuclear transport. SUMO-1 modification of RanGAP1 facilitates binding of the modified 
protein to the nuclear pore complex. This tightly bound RanGAP1 was shown to be crucial in 
nuclear import assays in vitro and soluble RanGAP1 could not substitute for it. One way 
SUMO affects the function of its substrates is sumoylation on otherwise ubiquitination 
specific lysine residues. PCNA or IκBα are examples for this phenomena. In the case of 
PCNA sumoylation and ubiquitination compete for the same site whereas sumoylation was 
shown to alter PCNAs function by inhibiting ubiquitination dependent post-replication DNA 
repair. Also the sumoylation of ubiquitination sites of particular high molecular weight 
proteins after various cellular stress conditions with SUMO-2 and-3 chains was reported. This 
sumoylation pattern was reversed after normalization of the cellular stress stimuli, suggesting 
a role of sumoylation to inhibit those sites for ubiquitination mediated proteasomal 
degradation (12).  
 
 
1.1.4  NEDD8 modification 
 
The UbL-modifier NEDD8 (Neuronal-precursor cell-expressed developmentally down-
regulated protein 8) was originally discovered as a down regulated protein in neural precursor 
cells during the development of murine brain. The 76 amino acid big modifier is very similar 
to Ubiquitin in size, structure and charge distribution. Both modifiers share an almost 60% 
sequence identity. The most prominent neddylated substrates are the cullin family, which 
comprise in human six members (Cul-1,-2,-3,-4a,-4b,-5). Cullins serve as scaffold/bridge 
proteins in multi subunit ubiquitin ligase complexes also called CRLs (cullin-RING ligases). 
The C-terminus of a cullin integrated in such a complex serves as binding site for Roc1 or 
Roc2, which are E2 binding adaptors. Roc1 or Roc2 attract and bind an E2 conjugating 
enzyme, which brings ubiquitin to the complex required for CRL-substrate ubiquitination. 
The N- terminus of a CRL integrated cullin serves in most cases as binding site for a variable 
adaptor protein. On this adaptor protein (or direct to the cullin N-terminus) binds a substrate-
targeting module, which determines the pool of substrates connecting to the specific CRLs. 
Via the different composition of mainly those substrate recognition modules, ∼400 different 
CRLs have been described in human. It is believed, that ∼20% of all proteins targeted for 
proteasomal degradation are polyubiquitinated by CRLs. The C-terminal neddylation of 
cullins assembled in CRLs was shown to enable a sufficient polyubiquitination of the CRL 
substrate protein (13, 14). Also other neddylated substrates have been described. The E3 
ligase MDM2, which ubiquitinates p53, may also neddylate p53, which inhibits its 
transcriptional activity (15). The VHL (von Hippel–Lindau) tumour suppressor protein is the 
cause of the familial VHL disease (cancer syndrome) and most sporadic RCC (renal clear-
cell) carcinomas. Needylation of VHL has been reported to be important for VHL binding to 
fibronectin and to promote its matrix assembly. A non-neddylateable VHL mutant failed to 
bind to and promote the assembly of fibronectin. Deregulated ECM, as well as abnormal cell-
matrix interactions are hallmarks of solid tumors. Alterations in the fibronectin component of 
the ECM have been correlated with cellular transformation, like VHL-associated 
tumorigenesis (16). Also BCA3  (breast cancer associated protein 3) was shown to be a 
NEDD8 substrate and to function as a tumor suppressor upon modification. When NEDD8 is 
removed from BCA3, oncogenes are no longer suppressed, resulting in resistance to apoptosis 
and excessive cell proliferation.  
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Neddylation of BCA3 suppresses NFκB-dependent transcription through its ability to bind to 
p65 and the cyclin D1 promoter (17). The EGFR (epidermal growth factor receptor) functions 
as a tyrosine kinase upon activation by its ligands, which triggers DNA synthesis and cell 
proliferation. It was shown, that EGFR neddylation enhances its subsequent ubiquitination, 
resulting in its endocytosis and sorting for lysosomal degradation (18). 
 
 
1.1.5  ISG15 modification 
 
Human ISG15 (IFN-stimulated gene 15) has a size of 157 amino acids and consist of two 
domains, where each domain is structurally similar to ubiquitin. ISG15, like other ISGs, is an 
interferon-inducible gene product, which is strongly upregulated upon viral or bacterial 
infection. It was further described to be upregulated after LPS (Lipopolysaccharide) and 
double stranded RNA stimuli. The first discovered substrate of this modifier was Spi2a (serin 
protease inhibitor 2a), which regulates intracellular proteases in antigen-presenting cells. In 
general ISG15 is considered as a broad-spectrum inhibitor of virus production upon viral 
infection. Antiviral activity associated with viral or host protein ISGylation has been reported 
for DNA and RNA viruses, like HCMV (human cytomegalovirus), HSV (herpes simplex 
virus), SV (Sindbis virus) and HCV (hepatitis C virus). Mass spectrometric analysis has led to 
the identification of at least 200 putative ISG15 target proteins. Many of them have crucial 
functions in the type I IFN response, including JAK1 and STAT1. ISGylation of those 
signalling proteins was shown to increase their activity to enhance the cellular response to 
interferons (19). This was achieved by e.g. induction of the antiviral effector enzymes PKR 
and RNase L. Those protein activations trigger a global inhibition of protein synthesis and 
virus replication. This is achieved through the phosphorylation of eIF-2α (for PKR) and 
breakdown of RNA (for RNase L). It was also shown that up on activation of PKR and RNase 
L an upregulation of ISG15 mRNA levels was achieved (20, 21). Upon viral infection, ISG 
induction occurs in two intervals: first an IFN-independent induction of a subset of ISGs is 
induced and second an IFN-dependent induction via the production of IFN-α/β follows. In 
many viral infections, IFN-independent ISG induction is mediated by IRF-3 phosphorylation, 
homodimerization, and nuclear translocation. Activated IRF3, in turn, induces the expression 
of type I IFN genes, whose products trigger strong induction of a subsets of ISGs, including 
IFN-β which after its release and ligand-binding to its receptor initiates IFN-dependent ISG 
induction via the IFN receptor and JAK/STAT signalling pathways. ISG15 has been reported 
in HBV (hepatitis B virus) to prevent virus-mediated degradation of IRF3 (interferon 
regulatory factor 3), thereby increasing the induction of IFNβ expression (22). ISG15 can also 
be secreted from stimulated cells by a yet not described mechanism and is believed to 
function as a cytokine to modulate the immune response. In this manner ISG15 was shown to 
stimulate interferon γ secretion by monocytes and macrophages, proliferation of natural killer 
cells, and chemotactic responses in neutrophils (23). Some viruses have developed specific 
strategies to counteract the activity of ISGs. The influenza B virus protein NS1B is able to 
bind to ISG15 and by doing so inhibits protein ISGylation (24). ISG15 overexpression in cell 
culture was shown to hinder efficient budding of Ebola VP40 virus like particles. The Ebola 
virus matrix protein VP40 is a major viral structural protein and plays a central role in virus 
assembly and budding at the plasma membrane of infected cells. VP40 needs to be 
ubiquitinated to facilitate efficient viral budding. It has been reported, that the cellular E3 
ligase Nedd4, which ubiquitinates VP40, gets ISGylated, which inhibits its enzymatic activity 
hindering efficient Ebola VP40 virus like particle budding (25).  
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1.1.6  Human DUBs and ULPs and examples of their function 
 
All DUBs and ULPs are Cystein proteases, with the exception of the JAMM 
metalloproteases, which cleave the modifier from the substrates in a Zn2+- and ATP-
dependent manner. So far approx. 100 human DUBs have been identified, and based on the 
sequence similarities, they have been classified into five distinct subfamilies: USPs 
(Ubiquitin-specific proteases), UCHLs (Ubiquitin carboxyl-terminal hydrolases), OTUs 
(Otubain proteases), MJDs (Machado-Joseph disease proteases) and JAMMs 
(Jab1/MPN domain metalloenzymes) (6). The human ULPs are represented by the SENP 
(sentrin specific peptidase) family (12). 
 
 
1.1.7  USPs 
 
USPs (Ubiquitin-specific proteases) belong to the largest and most diverse DUB family. 
Those enzymes have specific substrates and can regulate distinct signaling pathways at 
various levels. Examples include USP7, which stabilizes p53 and MDM2 (E3 ligase of p53) 
in cells (26). CYLD is a K63-linked Ub chain specific USP in the NF-κB pathway that 
inhibits the activation of the IKK kinase complex (27). USP28 stabilizes the transcription 
factor c-myc (28), while USP8/UBPY affects endosomal trafficking (29). USP14 is associated 
with the proteasome and is required for ubiquitin recycling by removing K48-linked Ub 
chains from proteasomal substrates (30). Beside the main characteristic of USPs, to cleave 
ubiquitin linkages, members of this family have also been described to have dual activities 
towards UbL-modifier. For example USP2, USP5 and USP14 are able to hydrolyze ISG15 
conjugates. Those activities were previously elucidated by the ability of those USPs to bind to 
the suicidal probe ISG15-VS (31). Those chemical probes are widely used to characterize 
catalytic active cysteine deconjugases. Those probes contain besides Ub or a specific UbL a 
reactive compound, which binds and inhibits in most cases the catalytic site of the targeted 
enzyme (32). Several USPs have been described to comprise a dual specificity to Ub and 
NEDD8 (33). For instance USP21 has been described to recognize NEDD8 and to be able to 
deneddylate cellular substrates (34). Several USPs have been implicated in malignant 
transformation including for example the product of the cylindromatosis or turban tumor 
syndrome gene CYLD, which was identified as a regulator of the NF-kB pathway (2). Some 
USPs exert distinct growth regulatory activities by acting as oncoproteins or tumor suppressor 
proteins (3). The size of USPs ranges between 330 and 3500 amino acids and their catalytic 
domain comprising conserved cysteine and histidine boxes has a size between 300 and 850 
amino acids. The N- and C-terminal extension domains of USPs determine their substrate 
specificity and are involved in protein-protein interaction and determination of cellular 
localization (35). Structural studies have defined the USP domain fold, and 5 crystal 
structures of mammalian USP domains have been published (36-40). USP domains share a 
common fold, which is conserved in almost all USPs. This structure was defined from the 
crystal structure of USP7. This USP domain resembles a three-domain architecture 
comparable to an open hand formation containing Thumb, Palm and Fingers. The Thumb 
consists of eight α helices, while the Palm contains eight central β strands and two helices. 
The fingers are comprised of four β strands in the center and two at the tip. The catalytic triad 
residues are located between the Thumb (Cys) and Palm subdomains (His/Asp) (37).  
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1.1.8  UCHLs  
 
The UCHL (Ubiquitin carboxyl-terminal hydrolase) family is comprised of 4 members 
(UCHL1, UCHL3, UCHL37 and Bab1), which have generally small sizes (20-30 kDa). Their 
sequences are conserved among species with approximately 40% homology. UCHL1 is 
highly expressed in neurons and reduced levels have been observed in various 
neurodegenerative diseases. Mutations in the UCHL1 gene have been reported to be linked to 
Parkinson’s disease and expression of UCHL1 was shown to rescue synaptic dysfunction in 
Alzheimer’s disease model mice (41, 42). Abnormal overexpression of UCHL1 has been 
reported to relate to several forms of cancer (43). UCHL3 is expressed in various tissues and 
cleaves beside Ub also neddylated substrates. Studies using UCHL3 deficient mice have 
suggested a role in growth and cell survival (44, 45). UCHL37 specifically cleaves K48-
linked Ub chains and is associated with the 19S regulatory subunit of the 26S proteasome 
(46).  
 
 
1.1.9  OTUs 
 
OTUs (Otubain proteases) are a recently identified DUB family with so far approximately 15 
members. They belong to the ovarian tumor superfamily of proteins with more then 100 
members. OTU homologues in different species show a high degree of homology. Also their 
enzymatic cores are highly conserved but their substrate specificities appear to be quite 
diverse. Otu1 (otubain 1) has been shown in vitro to cleave K48-linked Ub chains and to 
decrease global Ub conjugate level after overexpression in vivo (47), (48). Otu2 (otubain 2) 
was shown to be inactive in vitro against ubiquitin peptide/isopeptide-linked substrates (49), 
but was able to cleave the flurogenic probe Ub-AMC (50). Other human OTU proteins known 
to have DUB activity are A20, Cezanne, TRABID, DUBA and VCIP135. A20 is a dual active 
enzyme comprising DUB and E3 ligase activities, which are required for termination of TLR 
(Toll-like receptor) signalling resulting in NF- B activation and inactivation of TNF (tumour 
necrosis factor) induced cytotoxicity and apoptosis (51, 52). Similar to A20, Cezanne has 
been shown to inhibit NF-κB through modulation of the ubiquitination state of two of its 
positive regulators, TRAF6 and RIP-1 (53, 54). Cezanne was shown accumulate in acute 
lymphoblastic leukemia and Burkitt lymphoma (55). While the precise role of Cezanne in 
cancer is unknown, its inhibition of NF-κB suggests that Cezanne may act as a tumor 
suppressor. VCIP135´s DUB function was described to be required for Golgi membrane 
fusion (56) and DUBA1 was reported to deubiquitinate the E3 ligase TRAF3 resulting in 
negative regulation of IFN-1 signalling and down regulation of the innate immune response 
(57). 
 
 
1.1.10  MJDs 
 
MJDs (Machado-Joseph disease proteases) are conserved cysteine proteases that include four 
human DUBs (Ataxin-3, ATXN3L, Josephin-1 and Josephin-2). MJDs are conserved 
throughout eukaryotes and share a common cysteine protease domain (Josephin domain) of 
approximately 180 amino acids. The first discovered and best characterized MJD is Ataxin-3. 
Insertion of a polyglutamine repeat in Ataxin-3 was shown to cause the neurodegenerative 
Machado-Joseph disease giving this DUB class its name. In contrast to ataxin-3, much less is 
known about the other three human MJDs (58).  NMR and crystallization based structural 
analysis has been published for Ataxin-3 but for no other MJDs (59). ATXN3L, Josephin-1 
and -2 have been shown to possess DUB activity but no substrates are described so far (58). 
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1.1.11  JAMMs 
 
JAMMs (Jab1/MPN domain metalloenzymes) comprise 5 members with described DUB 
activity. With a big exception to all other DUBs, JAMMs are lacking a catalytic cysteine. 
Instead, they are metalloproteases, which coordinate a catalytically essential zinc ion within 
their active sites. The three best known JAMMs are Poh1, Jab1 and Brcc36. Poh1 is a subunit 
of the 19 S subcomplex which releases K48-linked polyUb chains from substrates targeted to 
the proteasome for degradation. It has been suggested that Poh1 functions as a proteasomal 
“proofreading” device that determines the fate of incoming substrates as to whether they will 
be rescued or degraded (60).  Jab1 is a component of the CSN (COP9 signalosome), a 
multisubunit complex very similar to the 19S proteasome lid complex, which cleaves NEDD8 
of the cullins assembled in CRLs (61). Brcc36 was shown to recognize and cleave particular 
K63-linked ubiquitin chains. Among others Brcc36 is a component of the BRCA1-A 
complex, which specifically recognizes K63-linked ubiquitinated histones H2A and H2AX at 
DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage 
at double-strand breaks (62).  
 
 
1.1.12  ULPs 
 
Human ULPs (Ubl-specific proteases) comprised the SENP (sentrin specific peptidase) 
family, which consist of eight members. They are all homologues of the earlier discovered 
yeast ULP1 homologue. ULP1 and SENPs are classified as a large group of cysteine 
proteases, which catalyze cleavage of the peptide bond after the C-terminal glycine to activate 
the modifier as well as deconjugate them from their substrate. ULP1 and SENPs are 
comprised of a ∼200 amino acid long catalytic domain containing the active residue triad Cys, 
His and Asp. Their N- terminal domain has a variable length and sequence and is responsible 
for localisation, target interaction and specificity. One member, SENP8, also called NEDP1 or 
DEN1, is specific for NEDD8 activation and substrate deconjugation. SENPs have been 
shown to have distinct sub-cellular localizations controlled by their non-conserved N-terminal 
regions.  SENP1 and SENP3 are predominantly localized into the nucleus. SENP2 isoforms 
are found in the cytoplasm, binding to the nucleoplasmic side of the nuclear pore complex ore 
localize to PML nuclear bodies. SENP6 is localized in the cytoplasm (12). 
 
 
1.2  Human virus encoded DUBs and their described function 
 
Nairoviruses and Arteriviruses, two unrelated RNA virus families, have been shown to 
express OTU domain-containing proteases. The L-protein of Nairoviruses, e.g. from the 
highly pathogenic CCHFV (Crimean-Congo Haemorrhagic Fever Virus) has been shown to 
process Ub and ISG15 conjugates and pro-ISG15 and pro-NEDD8 in vitro. CCHFV was also 
able to cleave Ub and ISG15 conjugates in cells. ISGylation and ubiquitination mediate 
antiviral effects. The NF-κB immune pathway is regulated by ubiquitination. CCHFV-L was 
described to inhibit NF-κB activation by the inhibition of endogenous p65 nuclear 
translocation upon TNFα stimulation (63). The SARS corona virus encoded PLpro protein 
was described to show deubiqitinase and isgylase activity in vitro. It is an enzyme with dual 
function first described to carry out N-terminal processing of the viral replicase polyprotein 
and then later also to cleave K48-linked polyubiquitin chains and ISG15 pro-peptides in 
vitro. Crystallization of PLpro revealed that it belongs to the USP family but its function as a 
DUB in the course of infection has not been demonstrated (64). Also the human corona virus 
NL63 was reported to encode the PLP2 protein, an enzyme with dual function.  
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PLP2 was also first described to be involved in viral replicase polyprotein processing and 
later on found to posses DUB activity. PLP2 was able to cleave K48-linked Ub chains and 
bind to the Ub-VS suicidal probe in vitro (65). Also the adenovirus encoded protease adenain 
has been described as an enzyme with dual function. Adenain is a nuclear and cytosolic 
protein. It was first described to be involved in virion maturation by cleaving e.g. viral capsid 
precursor and to be involved in cell lysis and release of the virions by cleaving cytoskeletal 
proteins (66). Adenain was described to cleave K48-linked Ub chains and ISG15 pro-peptides 
in vitro. During adenoviral infection the overall levels of ubiquitinated proteins (especially in 
the nucleus) decreased with increased adenain expression levels. The involvement of the 
adenain comprised DUB activity in the viral life cycle is not elucidated and no substrates are 
described yet (67). The HHV (human herpesvirus) family comprises eight members, which 
are subcategorized in α-, β- and γ- herpesviruses according to their site of latency. All human 
herpesviruses encode for a large tegumental protein. The N-termini of all of these proteins 
have been shown to contain a conserved region with comprised DUB activity (68). The first 
discovered member was UL36 of HSV1, which was detected by usage of the suicidal probe 
Ub-VME in HSV-1 infected cell lysates. The crystal structure of a mouse herpesvirus 
homologue, MCMV (murine cytomegalovirus) suggests that the herpesviral DUBs represent a 
new family of deubiquitinating enzymes, which is called “herpesvirus tegument USPs”. 
Among the best characterized UL36 homologues in human are BPLF1 from Epstein-Barr 
virus, UL48 from human cytomegalovirus and ORF64 from Karposi Sarcoma virus. UL36 
was shown in further investigation to cleave K48-linked Ub-chains in vitro (69). In earlier 
work a null mutant was generated in the UL36 gene to elucidate its role in the virus life cycle. 
Absence of UL36 lead to failure in targeting capsids to the correct maturation pathway 
resulting in accumulation of DNA-filled capsids in the cytosol not maturing into enveloped 
viruses (70). It remains unclear if this detected phenotype is due to elimination of UL36´s 
DUB activity because the UL36 null mutation, containing an internal deletion of amino acid 
362-1555, does not eliminate the active site residues but may interfere with folding and 
enzymatic activity. Also UL48 was shown to bind to the DUB probe Ub-VME and cleave 
K48-linked Ub-chains in vitro as described for UL36. Its catalytic active Cys- and His- 
residues were characterized via mutation analysis (71). Orf64 from KSHV was shown to be 
capable of deubiquitinating cellular proteins in vitro and in vivo. Orf64´s DUB activity was 
detectable against K48- and K63-linked Ub chains in vitro. Also the catalytic active cysteine 
was characterized via mutation analysis. Cell fractionation studies revealed that Orf64 is 
localized in the cytosol and nucleus. To test the function of ORF64, siRNA (short interfering 
RNA) knockdown studies on latently infected cell, which were induced into lytic replication, 
were conducted. The depletion of Orf64 by siRNA resulted in decreased lytic viral 
transcription and decreased lytic protein expression (72).  
 
 
1.3  The role of  Ubiquitin and UbL-modifiers in the life cycle of human viruses 
 
Given the central role of Ub- and UbL-modifications it is not surprising that many pathogens 
have devoted a considerable part of their genetic information to the production of proteins that 
mimic, block or redirect the activities of their host conjugating/deconjugating machineries. 
Modulation of those pathways is involved in virtually every step of the virus life cycle 
including virus entry, replication and assembly of new virus particles, immunity avoidance 
and virus exit. 
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1.3.1  Viral entry 
 
Viral entry can be broadly defined as all events, leading to the arrival of the uncoated virus 
genome into the nucleus. HSV (Herpes simplex virus) entry into cells is a multistep process 
that engages the host cell machinery. In experiments, were the proteasome was blocked by 
usage of proteasomeal inhibitors, viral entry was disabled at an early step, after capsid 
penetration into the cytosol but prior to capsid arrival at the nuclear periphery. In addition, 
HSV successfully entered cells in the absence of a functional host ubiquitin-activating 
enzyme, suggesting that viral entry is ubiquitin independent. It was proposed, that 
proteasomal degradation of virion and/or host proteins is required for efficient delivery of 
incoming HSV capsids to the nucleus. The candidate proteins remain to be elucidated (73). 
 
 
1.3.2  Viral replication 
 
In the case of host replication interference, generally DNA tumor viruses modulate the cell 
cycle to enhance their own replication. A common mechanism shared by these viruses, is to 
target cell cycle regulator proteins for degradation, which often results in cell transformation. 
A classical example is the viral mediated down regulation of the tumor suppressor p53. The 
HPV (human papillomavirus) -16 and -18, E6 proteins redirect the cellular single protein E3 
ligase E6AP to mediate proteasomal degradation of p53, which contributes to their 
oncogenicity by allowing uncontrolled cellular proliferation without induced apoptosis (74). 
A more common mechanism to control the turn over of particular cellular proteins is the 
manipulation of CRLs (cullin-RING-ligases). Examples for viral targeting of CRLs are the 
HPV-16 and -18, E7 proteins, which function as a substrate-binding module in a cullin 2 
based CRL. This assembled complex targets the Retinoblastoma protein (pRb), a tumor 
suppressor controlling G1-S-phase transition, for proteasomal degradation, shutting of this 
cell cycle arrest point (75). The Adenovirus proteins E1B55K and E4orf6 form a dimer, 
which functions as a substrate binding module in a cullin 5 based CRL, targeting the tumor 
suppressor p53 and the MRN- (Mre11, Rad50, Nbs1) complex, which is involve in DNA 
double strand break repair, for proteasomal degradation (76). E1B55K also contains a 
consensus site for sumoylation responsible for its nuclear localization. A sumoylation site 
mutant (K104R) showed altered localization and reduced ability to bind to p53, which also 
resulted in reduced cell transformation rates (77). The adenovirus E4orf4 and the HPV 
encoded E2 proteins were shown to inhibit the cell cycle by interfering with the APC 
(anaphase-promoting complex). APC is a cellular E3 ubiquitin ligase, which is essential for 
progression through the M-phase. Both viral proteins were additional described to inhibit the 
degradation of cyclin B resulting in a G2/M phase arrest (78). SV40 (Simian-Virus 40) 
expresses its LT (large T antigen), which binds to the SCF (Skp1, Cullin1, F-box)-complex 
(cullin1 based CRL) by inhibiting the substrate binding module F-box protein Fbw7. Most of 
the Fbw7 targeted substrates are potential cell cycle regulator or oncogenes like cyclin E, c-
Myc, c-Jun and Notch, which up on inhibition of Fbw7 get stabilized (79). The HPV encoded 
E2 protein and the adenovirus E4orf4 were shown to inhibit the cell cycle by interfering with 
the APC. Both viral proteins were additional shown to inhibit the degradation of cyclin B 
resulting to a G2/M phase arrest (80). Cytidine is a component of RNA, which is formed 
when cytosine is attached to a ribose ring. After infection of RNA retroviruses, host cells are 
trying to diminish cytidine to disturb viral replication. The cellular APOBEC- (apolipoprotein 
B mRNA editing enzyme catalytic polypeptide-like) family are mRNA editing enzymes, 
which edit cytosine to uracil essential for RNA synthesis.  
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It has been shown that APOBEC3G was able to diminish the non-coding strand of the HIV 
genome by converting deoxycytosin to deoxyuracil resulting in guanin to adenin 
hypermutations in the viral coding strand, restricting its propagation. To prohibit this pathway 
HIV encodes for the Vif protein, which functions as a substrate-targeting module in two 
described Cul5 based CRLs that target APOBEC3G for polyubiquitination and proteasomal 
degradation (81, 82). Instead of hijacking cellular E3 ubiquitin ligases several viruses have 
been described to encode their own E3 ubiquitin ligases within their genome. HSV-1 encodes 
for the ICP0 (infected cell protein 0), an E3 ubiquitin ligase, which has been shown to induce 
polyubiquitination and degradation of a variety of proteins, including the PML protein, G1/S-
phase specific cyclin D3, p53 and the DUB USP7. ICP0 contains two E3 ligase sites. One of 
those sites recruits the cellular E2 ubiquitin conjugating enzyme UbcH5a as well as the DUB 
USP7. ICP0 has also been shown to undergo autoubiquitination, which was reversed by the 
recruited USP7. ICP0 was also shown to facilitate polyubiquitination and proteasomal 
degradation of USP4. When cells were infected with an ICP0 null mutant an enhanced viral 
replication was detected. Among all known targeted proteins of ICP0, the polyubiquitination 
and degradation of PML was suggested for the detected replication phenotype (83). Also 
KSHV (Kaposi sarcoma herpesvirus) was shown to encode a protein with E3 ubiquitin ligase 
function, called RTA (replication and transcription activator). RTA was earlier described to 
serves as transactivator protein, which is essential for activation of viral DNA replication 
upon initial infection and reactivation from latency. This viral multifunctional protein was 
shown to target several RTA repressor, like K-RBP (KSHV-RTA binding protein) and Hey1, 
a cellular transcriptional repressor, for polyubiquitination and proteasomal degradation. This 
RTA mediated repression of those two transcriptional repressors was shown to be essential 
for the reactivation of lytic DNA replication (84, 85) 
 
 
1.3.3  Immune response 
 
In addition to altering the cell cycle, viruses manipulate CRLs to interfere with the immune 
response of the host cells. HIV-1 (Human immunodeficiency virus 1) encodes the Vpu-
protein, which functions as a substrate-binding module in the SCF complex. The Vpu 
modified CRL induces the polyubiquitination of the CD4 receptor in the ER-membrane, 
which causes its cytosolic translocation and proteasomal degradation. CD4 functions as a co-
receptor for the TCR (T-cell receptor). Both receptors together mediate adaptive immunity by 
binding to MHC class I (86). Viruses often activate the antiviral interferon response during 
infection. The JAK-STAT pathway is an interferon induced cytokine signaling pathway in 
mammals and a key player in antiviral defense. STAT (signal transducer and activator of 
transcription) proteins comprise a family of transcription factors important in cell growth, 
survival and differentiation, which get activated after pathway induction. The rubulavirus 
encoded V protein serves as a substrate-targeting module in a Cul4a based CRL. It also binds 
directly to STAT2 (for human parainfluenza virus type 2) or STAT2 can be used to recruit 
STAT1 (for simian virus 5 and mumps virus). STAT2 or the heterodimer STAT1/STAT2 get 
connected to the CRL via the V protein and in following polyubiquitinated as signal for 
proteasomal degradation (87). The mumps virus encoded V protein was shown to target 
STAT3 directly via this above described composition, also as mechanism to diminish the 
antiviral response (88). There are also viral proteins known, which dislocate unwanted 
proteins from the ER. The HCMV (human cytomegalovirus) encoded US11 and US2 proteins 
dislocate MHC-I from the ER to the cytosol, were it becomes polyubiquitinated and 
proteasomal degraded (89). Also the KSHV (Kaposi's sarcoma herpes virus) encoded proteins 
K3 and K5 have been shown to down-regulate MHC-I mainly on the cell surface.  
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K3 and K5 are membrane proteins containing an N-terminal located E3-ligase domain, which 
adds K63- linked Ub chains to MHC-I, mediating its endosomal sorting and lysosomal 
degradation (90). The destruction of MHC-I decreases antigen presentation to T cells, 
avoiding immune recognition. The CD4 receptor is a co-receptor, which assists the TCR (T 
cell receptor) of helper T-cells by antigen-presenting cell recognition essential for innate 
immunity activation. After cellular CD4 synthesis, the protein gets located within the ER-
membrane and sorted to the cell outer membrane. The HIV encoded Vpu protein is a 
transmembrane protein, which is also integrated into the ER-membrane. It binds to CD4 and 
βTRCP, a substrate targeting module in the Cul1 based SCF complex. This CRL interaction 
modulates CD4 polyubiquitination and proteasomal degradation, resulting in inefficient 
antigen-presenting cell recognition of helper T-cells (91). As described above, induction of 
ISG15 expression upon viral infection appears to be a broad-spectrum inhibitor of virus 
production. Influenza B virus infection causes strong induction of ISG15 expression. Its viral 
encoded NS1 protein was found to bind to ISG15, preventing it from binding to its E1 
activating enzyme UBE1L, causing inhibition of cellular ISGylation (92). 
 
 
1.3.4  Viral budding 
 
RNA viruses, like HIV-1 and RSV (Rous sarcoma virus) complete their replication cycle by 
forming vesicles that bud from the plasma membrane. The Gag polyprotein has been reported 
to be necessary and sufficient for the assembly and budding of virus-like particle. A central 
located Gag protein domain, called L (late) domain, was reported to bind to cellular proteins 
involved in the host VPS (vacuolar protein sorting) pathway, a cellular budding process that 
formats multivesicular bodies, very similar to virus budding. Among those recruited cellular 
proteins are Nedd4-family E3 ligases, which have been shown to facilitate ubiquitination of 
the viral Gag-protein. Gag ubiquitination is correlated with successful virus release, also 
facilitating its own sorting into viral vesicles as they bud from the plasma membrane (93). 
Tsg101 (tumor supressor gene 101) is involved in vascular protein sorting and multivesicular 
body biogenesis by binding to monoubiquitinated proteins. Also Tsg101 was shown to bind to 
the ubiquitinated Gag protein by binding to Gag and ubiquitin. This interaction was shown to 
be essential for viral budding and release of HIV and Ebola virus (94).  
 
These above described findings emphasize the pivotal role of Ub/UbL 
conjugation/deconjugation in modulating critical aspects of the virus-host cell interaction. 
 
 
1.4  Introduction to EBV 
 
EBV is a 172 kb long double-stranded DNA tumor virus, which establishes latent infections 
in 90% of the human population worldwide. Infection occurs in most cases during childhood 
with no or mild symptoms. Infection occurring in adulthood is known to cause a benign 
lymphoproliferative disease called “infectious mononucleosis”. This viral illness is 
characterized by moderate symptoms like fever, sore throat and swollen lymph glands. EBV 
is associated with a variety of malignancies of lymphoid cells, like Burkitt´s lymphoma, 
Hodgkin´s lymphoma and NK- and T-cell- lymphomas as also of epithelial cells, like 
nasopharyngeal carcinoma and gastric carcinoma. Like other herpesviruses EBV has a latent 
and a lytic life cycle. Epithelial cells of the oropharynx are the site of primary infection and 
are also believed to be the major site for viral replication. B-lymphocytes have been shown to 
serve as sites for the viral latent cycle and life long persistence. The EBV-genome does not 
normally integrate into the cellular DNA but persists as circular episome in the host cell.  
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The viral latency comprehends the expression of a subset of latent proteins and an array of 
transcribed non-coding RNAs (EBERs) and microRNAs depending of the type of latency 
(Type I, II, III). Those nine latent proteins are comprised of six “EBV nuclear antigens”, 
called EBNA-1, -2, -3A, -3B, -3C and LP and three “latent membrane proteins”, called LMP-
1, -2, and -3. The viral latency is well studied and understood to a higher degree then the 
regulation of the viral lytic phase (95, 96). Upon induction of the lytic phase the first 
detectable expressed proteins are the two immediate-early gene products BZLF1 and BRLF1. 
Both proteins transactivate viral promoters, which leads to an ordered cascade of viral early 
and late gene expression. Early gene products include proteins involved in viral DNA 
replication and DNA metabolism. The lytic phase of DNA replication is dependent on seven 
viral replication proteins: BZLF1, binding to the oriLyt (origin of lytic phase); BALF5, a 
DNA polymerase; BMRF1, a polymerase processivity factor; BALF2, a single-stranded 
DNA-binding protein and BSLF1, BBLF4, BBLF2/3 proteins comprising a primase-helicase 
complex. Viral lytic replication occurs in discrete nuclear sites, named replication 
compartments, in which viral replication proteins are assembled. Induction of the EBV lytic 
program results in inhibition of cellular DNA replication as well as explosive replication of 
viral DNA (97). 
 
 
1.5  The role of  ubiquitin and UbL-modifiers in the EBV life cycle 
 
Nedd4 ubiquitin ligase family members have been reported to have a function in the 
maintenance of EBV latency in B lymphocytes. The BCR (B cell receptor) is known to 
mediate reactivation of the lytic cycle from the latent state. This is achieved by BCR cross-
linking resulting in activation of signaling pathways, which initiates the viral transactivator 
BZLF1. Among others Lyn and Syk are two cytoplasmic tyrosine kinases, which upon 
binding to activated BCR mediate activation of BZLF1. The viral latent protein LMP2A 
contains two PPPY motifs, which were shown to recruit Nedd4 family members. After 
LMP2A binding to Lyn and Syc the recruited Nedd4 E3 ligases facilitate the 
polyubiquitination of those two tyrosine kinases, which causes their proteasomal degradation. 
The depletion of Lyn and Syk prevents signaling of activated BCR resulting in the 
maintenance of the latent cycle (98). The lytic switch gene BZLF1 was found to be modified 
by SUMO-1. Unconjugated SUMO-1 level in cells are quite low. It has been shown, that 
BZLF1 competes with the PML-protein for SUMO-1 required for their both modification. By 
doing so BZLF1 degreases PML-protein sumoylation, causing the inhibition of PML body 
formation. Among others PML body formation is induced by type I and II interferons, 
induced upon viral infection, suggesting a function with an antiviral capacity. The disruption 
of PML bodies, which was demonstrated by all classes of herpesviruses, suggests that this 
function is important for efficient lytic replication. It has also been shown, that sumoylation of 
BZLF1 decreases its transactivating ability (99). BZLF1 was also shown to serve as a 
substrate binding module in a Cul2 and Cul5 based CRL. Those assembled CRLs were 
reported to target p53 for polyubiquitination and proteasomal degradation (100) as described 
already for other viruses above. EBNA3C is a critical component for EBV immortalization of 
infected B lymphocytes. EBNA3C was found to be modified with SUMO-1 and upon this 
modification co-localized with PML nuclear bodies. This co localisation was shown to 
decrease the effect of PML body formation, possibly due to competition among PML and 
EBNA3C for limited free SUMO-1 resources. The site of sumoylation was elucidated by 
usage of an EBNA3C truncated form. An EBNA3C 343-545 was not able to undergo 
sumoylation and did not co localize with PML nuclear bodies.  
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Since EBNA3C transcriptional activation is mediated by amino acids 365 to 545, which 
are required for binding to SUMO, EBNA3C modification with SUMO could be important for 
EBNA3C described transcriptional effects (101). EBNA3C was also shown to interact with 
the Rb protein and to facilitate its proteasomal degradation via the SCF-Skp2 complex. 
Overexpressed EBNA3C into EBV negative epithelial and lymphoid cell lines resulted in 
decreased Rb protein level. It has been shown, that the ability of EBNA3C to facilitate the 
degradation of Rb was down regulated by expression of a dominant negative SCF-Skp2 
complex. No down regulation of Rb was detected in the absence of EBNA3C (102). Most 
intracellular proteins are destroyed via polyubiquitination mediated degradation in the 
proteasome. Resulting peptide fragments of degraded antigens are presented at the cell 
surface in association with MHC-I for immune recognition (103). EBNA1 is the most 
prominent latent protein of EBV with the broadest array of function. It is known to be 
essential for the maintenance of the viral genome, transcription and translation of the viral 
DNA, viral host persistence and cellular transformation. It has been demonstrated, that the 
internal Gly-Ala repeat domain of EBNA1 was able to interfere with the proteasome resulting 
in its protection from degradation. As a result, no EBNA1 peptide fragments are assessable 
for MHC-I binding and presentation on the cell surface, impairing immune recognition (104). 
EBNA1 has also been shown to interact with the DUB USP7, which has also been described 
to deubiquitinate p53 and its E3 ligase Mdm2. EBNA1 and p53 compete for the same 
interaction site on USP7. EBNA1 was shown to have a ∼10 fold higher affinity to the USP7 
binding site then p53, being able to control p53 binding and deubiquitination. Functional 
studies were able to show, that binding of EBNA1 to USP7 was able to protect cells to 
undergo apoptosis by lowering p53 levels (105). Most substrates are ubiquitinated on lysine 
residues, although ubiquitination on Cysteine and Serine residues as the ubiquitination of N-
termini has also been reported. A database search identified several lysine free viral proteins, 
with lysine rich cellular and viral homologues. It is believed, that the comprehension of 
Lysine less proteins could be advantageous to viruses to protect them from polyubiquitination 
mediated degradation. The EBV encoded BHRF1 protein is a lysine less protein and a Bcl2 
(B-cell lymphoma 2) family member. Bcl2 as BHRF1 are responsible for the release of 
mitochondrial cytochrome C, controlling cellular apoptosis (106, 107). It was shown in 
apoptotic cells, that Bcl2 was polyubiquitinated and degraded. To elucidate the impact of the 
lysine residues within Bcl2 concerning its described function, all lysines were removed via 
site-directed mutagenesis. It was demonstrated, that this lysine less Bcl2 mutant was 
resistance to degradation and was able to inhibit cell apoptosis (108). It could be speculated, 
that the lysine less BHRF1 is also able to escape ubiquitination and degradation with resulting 
pro-apoptotic conditions. LMP1 is one of the EBV gene products, which are essential for B-
cell transformation. It is also the only EBV protein that has oncogenic potential in non-B 
cells. The family of IRFs (Interferon regulatory factors) comprise transcription factors, which 
are predicted to contribute to EBV oncogenesis through regulation of a spectrum of 
oncogenes or apoptosis related genes. IRF7 is a central regulator of type 1 IFN-mediated 
innate and adaptive immune responses. It has been shown that IRF7 is modified from TRAF6 
with K63-linked polyubiquitin, which protects the protein from proteasomal degradation and 
also causes its transcriptional activation. TRAF6 is a member of the TRAF protein family, 
which are involved in signal transduction controlling both innate and adaptive immune 
responses. TRAF6 has also been shown to comprise E3 ubiquitin ligase activity. TRAF6 and 
its E3 ligase activity are required for LMP1 stimulated IRF7 ubiquitination. A20 is an enzyme 
with dual function, comprising DUB and E3 ubiquitin ligase activity in one protein. Further it 
has been shown that LMP1 induces A20, which upon induction negatively regulates IRF7 
transcriptional activity by deubiquitinating IRF7.  
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A DUB deficient truncation or point mutation reduced the ability of A20 to inhibit IRF7, a 
ligase mutant didn’t show any effect. Knockdown of A20 resulted in an increase in 
endogenous IRF7 K63-linked polyubiquitination and transcriptional activation (109, 110). 
Upon EBV infection, several cellular DUBs are known to increase in activity including USP-
5, -7, -13, -15 and -22. Those DUBs recruited by EBV may stabilize β-catenin in latently 
infected B-cells. β-catenine is a key component of the Wnt signaling pathway that regulates 
growth and differentiation of cells. Wnt signaling deregulation has been implicated in cancer 
development and could also play a role in EBV associated cancer development (111). An 
overview of all the interactions of EBV with the cellular ubiquitin and ubiquitin like-
modification system introduced above, are visualized in figure 2. 
 
 
Figure 2. EBV encoded ORFs interfere with the ubiquitination and UbL-modification system at different sites.  
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2.  AIMS OF THIS STUDY 
 
The general aim of the work presented in this thesis, was to elucidate and characterize novel 
deubiquitinating enzymes (DUBs) or ubiquitin-like proteases (ULPs) encoded within the 
genome of Epstein-Barr virus (EBV).  
 
 
More specifically, we wanted to: 
 
- develop a bacterial screening assay based on usage of Ub/UbL-modifier reporter constructs,    
to test the EBV-ORFeome for encoded functional DUBs and ULPs 
 
- characterize the discovered DUBs and ULPs via mutation analysis and usage of functional 
reporter and probes 
 
- elucidate the functional role of EBV encoded DUBs or ULPs in the viral life cycle,      
including detection of interaction partners  
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3.  METHODS, RESULTS AND DISCUSSION 
 
 
3.1  Publication I  
 
 
"Epstein-Barr Virus encodes three bona fide ubiquitin-specific proteases" 
 
 
This publication was divided into a bioinformatics part and a biochemical orientated 
experimental part. The overall aim was it to predict in silico EBV encoded ORFs with distant 
functional homologues of human DUBs using sequence analysis methods. Candidate ORFs 
were further characterized by detecting their functional ability to process an ubiquitin 
conjugated reporter and probe construct. In following the in silico detected catalytic active 
cysteines were confirmed via mutation analysis.  
 
 
Bioinformatics approach: 
 
EBV encodes approximately 100 ORFs were most of them remain to be functional 
characterized. Given the essential role of DUBs within a cell, as described in previous 
chapters, a bioinformatics orientated strategy was developed with the aim to predict viral 
DUBs with distant functional human homologues. Four search strategies based on sequence 
analysis were used to identify putative DUBs encoded in the EBV genome. 
(i) Sequence alignment with the conserved C- and H-boxes of known DUB families. As 
mentioned before, all DUBs contain conserved regions within their catalytic domains, which 
are for most of them located around the catalytic active cysteine and histidine, also called C- 
and H-boxes. In the case of the JAMM DUB family, which are metalloproteases, only H-
boxes are present. A data set containing the sequences of human DUBs was aligned to the 
EBV ORF-eome by using the program CLUSTAL W. This widely used multiple sequence 
alignment program starts by doing a pair wise sequence alignment. Afterwards it generates a 
phylogenetic tree, a branching diagram showing the evolutionary relationships among species. 
Thereafter the program uses the phylogenetic tree to carry out a multiple alignment. 
Subsequently, sequence alignment with the BLAST (Basic Local Alignment Search Tool) 
program was performed. BLAST belongs to the most used sequence analysis methods and 
enables homology detection using pair wise sequence comparison. The characteristics of this 
program are short running times with a minimal sacrifice to distant sequence relationships. 
The resulting scores from a BLAST search have a well-defined statistical interpretation, 
making it possible to discriminate real matches from background hits (112).  
(ii) Pattern search of conserved catalytic domains is a family based method, which uses as 
search criteria the conserved sequence information assembled in a set of homologue proteins 
(113). Patterns are the occurrence of distinct amino acids, which are conserved throughout 
members of a certain protein family. In our study, family based search pattern were derived 
from the aligned C- and H-box sequences of the known human DUBs. Pattern search with 
those conserved boxes accomplishes a more stringed assessment of the possibility that 
identified domains might be true C- or H-box homologues.  
(iii) Hidden Markov Model (HMM)-based searches involve two steps. At first a statistical 
model from the sets of aligned sequences has to be build and second that model has to be 
compared to query sequences. HMM is a profile-based model, which is in general more 
sensitive than pair wise methods like described above.  
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HMMs are “trained” to make use of position specific scoring matrices, which represent the 
distribution of amino acids at each position in the conserved domains of particular protein 
families (114). In our studies family specific HMMs were trained from the aligned C- and H-
boxes of the different human DUB families.  
(iv) Identification of Cys and His residues that are conserved in homologues encoded by other 
members of the HHV (human herpes virus) family, followed by an HMM search was the last 
step of investigation. This analysis was based on the assumption that amino acid residues, 
which are critical for protein function, like enzymatic activity, may be conserved in the HHV-
family. In our studies we were able to locate conserved Cys and His residues in identified 
HHV-family ORF homologues by sequence comparison. In following the patches surrounded 
by the detected conserved Cys and His residues were searched for known DUB, C- and H-box 
patterns by using the DUB family specific trained HMMs.  
Via the above described search strategies several viral candidate ORFs were identified to 
comprehend possible DUB function. To select the most potential ORFs for following 
functional studies, scoring criteria were devised for each search, which were compiled in a 
global DUB score (see publication I for details). In total 16 EBV ORFs, which achieved the 
highest global DUB score, were selected for following functional studies.  
 
 
Biochemical approach: 
 
In order to evaluate the possible DUB function of the viral candidate ORFs we developed a 
bacterial screening assay. We cloned the candidate ORFs or ORF-domains in GST bacterial 
expression vectors and designed a reporter construct, which is comprised of Ubiquitin C-
terminal covalently linked with the N-terminus of GFP. Afterwards the Ub-GFP reporter 
construct and one of the GST-tagged EBV-ORFs at the time were transformed into E.Coli. 
The enzymatic activity of the candidate ORF was assayed by co-expression of the Ub-GFP 
reporter construct. Cleavage of the Ub-GFP reporter was detected via SDS-Page and Western 
blotting by usage of a specific antibody against an epitope located on the GST protein. To 
check the positive cleavage of the reporter during each assay, a GST fused USP19 (human 
DUB) was used. Via this method three EBV candidate ORFs could be identified, which were 
able to cleave the Ub-GFP reporter significantly above background. The N-terminal fragment 
of BPLF1, a large tegumental protein with earlier described DUB activity conserved amongst 
the HHV-family (68) was able to cleave the Ub-GFP reporter to the highest degree. The EBV 
ORFs BSLF1, known to function as an EBV primase, and BXLF1, known to function as an 
EBV thymidine kinase, were also able to cleave the reporter.  
In order to further characterize their DUB activity, those three proteins were overexpressed in 
bacteria and in following purified. The purified proteins were assayed by detection of 
cleavage of the flurogenic substrate Ub-AMC. This substrate contains the flurophore AMC, 
which upon 380 nm wavelength excitation and cleavage of the conjugated Ubiquitin starts to 
emit fluorescence with a wavelength of 460 nm (115). The whole in vitro assay was 
performed in a fluorometer, which detects the intensity of the cleaved substrate emission. All 
three EBV ORFs hydrolyzed Ub-AMC with different kinetics suggesting different affinities 
for the substrate. The ability of BSLF1 and BXLF1 to cleave Ub-AMC was significantly 
improved when equal amounts of immunoprecipitated proteins expressed in mammalian cells 
were taken for the assay. This circumstance may be explained by the impact of possible 
posttranslational modifications in increasing the activity of BSLF1 and BXLF1, which are not 
achieved in bacteria.  
In order to further characterize the DUB activity of BPLF1-N, BSLF1 and BXLF1, the 
predicted catalytic active cysteine residues were mutated to alanine residues to achieve 
catalytic inactive proteins.  
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These mutations were achieved by PCR mediated site-directed mutagenesis. For applying this 
technique complement DNA primer were designed, which were able to anneal to a patch 
containing the predicted active cysteine. The base triplet coding for cysteine were changed to 
the base triplet coding for alanine. The mutated plasmids were amplified by PCR. The 
mutated plasmids were separated from the pool of non-mutated plasmids by digestion of the 
metylated DNA of the unmutated DNA by the endonuclese DpnI. The unmutated DNA, 
multiplied and metylated by bacteria, is cleaved by DpnI. After transforming the remaining 
mutated DNA plasmid into bacteria, the linear plasmids is ligated to circular DNA, which is 
ready for amplification and protein expression. Via this method the catalytic inactive protein 
mutants BPLF1_C61A, BSLF1_C819A_C824A and BXLF1_C491A were generated. Their 
loss of catalytic inactivity was demonstrated by their inability to process the flurogenic probe 
Ub-AMC. The active cysteine of BPLF1 and BSLF1 were shown to be conserved throughout 
the HHV-family but just conserved among human γ-herpes viruses for BXLF1.  
Those three characterised EBV encoded DUBs, BPLF1, BSLF1 and BXLF1 are expressed in 
the nucleus during the early phase of the productive virus cycle. According to their annotated 
functions, they are involved in DNA replication and nucleotide metabolism pathways that are 
known to be regulated by posttranslational modifications like Ub and UbLs. The following 
publication (II) will discuss the essential role of BPLF1_N in virus replication. The DUB 
functions of BSLF1 and BXLF1 within the virus life cycle need to be investigated in further 
studies. 
 
 
3.2  Publication II  
 
 
“A deneddylase encoded by Epstein–Barr virus promotes viral DNA replication by 
regulating the activity of cullin-RING ligases” 
 
 
The overall aim of this work was it to elucidate the functional purpose of the discovered 
deneddylase activity comprised in the N-terminal fragment of the viral encoded BPLF1 ORF. 
We were able to confirm the deneddylase activity of BPLF1-N in different assays with 
different NEDD8 conjugated functional probes. We were also able to identify members of the 
cullin family as substrates of BPLF1-N´s deneddylase activity. We further elucidated the 
consequence of BPLF1-N binding and deneddylating cullins assembled in CRLs, which was 
the stabilization of CRL substrates involved in cell cycle regulation. We could show that this 
BPLF1-N controlled accumulation of replication regulating proteins was essential for an S-
phase like cellular environment and endoreduplication in BPLF1-N expressing cells. We 
further could demonstrate that the impact of BPLF1-N expression on viral genome replication 
was controlled by one stabilized CRL substrate, the DNA licensing factor CDT1. 
 
In order to extend the scope of the bacterial screening assay we designed new reporter 
constructs. Apart from the Ub-GFP reporter, we further constructed NEDD8-GFP, SUMO1-
GFP, SUMO2-GFP, SUMO3-GFP and ISG15-GFP reporter by linking the C-terminus of the 
UbL-modifier covalently to the N-terminus of GFP. We used an EBV-ORF library, were the 
entire ORF or ORF-domains were cloned into GST-bacterial expression vectors. The assay 
was performed by expressing the particular Ub/UbL-reporter construct together with one of 
the GST-tagged EBV-ORFs in E.Coli bacteria. The possible cleavage of the Ub/UbL-GFP 
reporter was detected via SDS-PAGE and Western blotting by usage of a specific antibody 
against an epitope located on the GST protein.  
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To check the positive cleavage of the Ub/UbL-reporter during each assay, GST-fused human 
DUBs or ULPs were used. The most striking result of this assay was it, that the N-terminal 
fragment of BPLF1 was able to process the NEDD8-GFP reporter with similar efficiency as 
the Ub-GFP reporter.  
In order to characterize further the novel discovered deneedylase activity of BPLF1, we 
performed functional assays. We detected an equal efficiency of bacterial expressed and 
purified GST-BPLF1-N processing the flurogenic substrates Ub-AMC and NEDD8-AMC 
(see for method explanation in publication I introduction and reference 115).  
We compared the ability of eukaryotic expressed BPLF1-N to bind to the Ub-VS and 
NEDD8-VS functional probes. Those probes are widely used to characterize catalytic active 
cysteine deconjugases. They contain besides Ub or a specific UbL a reactive compound, 
which binds and inhibits in most cases the catalytic site of the targeted cysteine deconjugase 
(32). The resulting interaction of the probe towards the enzyme can be visualized by a shifted 
enzyme protein band in Western Blot. For the assay we used an equal amount of eukaryotic 
expressed flag-BPLF1 and titrated different amounts of the Ub-VS and NEDD8-VS probes to 
the reaction. As a result we also detected here, that BPLF1-N was able to bind both probes 
with comparable efficiency.  
Taken together all three functional assays with the functional reporter and probes 
Ub/NEDD8-GFP, Ub/NEDD8-AMC and Ub/NEDD8-VS suggest similar affinities for 
BPLF1-N towards ubiquitinated and neddylated substrates. Ubiquitin and NEDD8 have the 
same size and share a similar structure and surface charge distribution. Given the high degree 
of homology between both modifiers the detected dual specificity for BPLF1-N is not 
surprising and is also shared by other USPs (116).  
Next we addressed the question, if BPLF1-N is able to deneddylate cellular proteins in vitro 
and in vivo. We expressed V5-tagged NEDD8 in eukaryotic cells and captured neddylated 
conjugates on anti-V5-conjugated sepharose beads. Those beads were incubated in vitro with 
purified GST-BPLF1-N, resulting in hydrolysis of cellular NEDD8 conjugates, which was 
detected in Western blots by usage of an anti-V5 antibody. The same experiment was 
repeated with the difference, that Flag-BPLF1 was co-expressed in the V5-NEDD8 
expressing eukaryotic cells. After lysing the cells and detecting the V5-NEDD8 conjugates in 
a Western blot, we observed that BPLF1-N was able to hydrolyse the neddylated cellular 
conjugates. Thus, BPLF1-N appears to be a true deneddylase.  
After this indication we were wondering which cellular neddylated substrates are targeted by 
BPLF1-N. The best characterized neddylated cellular proteins are the cullin family, which 
comprise in human six members: Cul-1,-2,-3,-4a,-4b,-5. The C-terminal neddylation of 
Cullins assembled in CRLs was shown to enable a sufficient polyubiquitination of the 
particular CRL substrate protein (13, 14). In our studies we could show, that BPLF1-N is able 
to deneddylate Cul1 and Cul4a in vivo. We co-expressed in eukaryotic cells Flag-BPLF1-N 
with V5-NEDD8 and Myc tagged Cul1 and Cul4a, which are two representative members of 
the cullin family. After lysing the cells and running their lysate on a SDS-PAGE, we were 
able to detect BPLF1-N´s ability to hydrolyze V5-NEDD8 conjugated Cul1 and Cul4a.  
After showing this effect we wanted to investigate, if the enzyme also binds to those two 
cullins. We transfected eukaryotic cells with Flag-BPLF1-N and Myc-Cul1 or Myc-Cul4a and 
performed co-immunoprecipitations (Co-IPs). Cell lysates were separated and the Co-IPs 
were conducted in both ways, using the Flag- and Myc- antibody. Both cullins were shown to 
bind to BPLF1-N, which was detected in following Western blots of the anti-Flag and anti-
Myc Co-IP fractions. After showing this interaction for overexpressed Cul1 and Cul4a, we 
repeated this Co-IP experiment performed with endogenously expressed Cul4a. We 
transfected eukaryotic cells with Flag-BPLF1-N and separated again the cell lysates, for Co-
IP experiments in both ways, with an anti-Cul4a and an anti-Flag antibody. Endogenous 
Cul4a was able to bind Flag-BPLF1-N, detected in the anti-Cul4a and anti-Flag Co-IP. 
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Neddylation of cullins integrated in CRLs enables the E3-ligase complex to polyubiquitinate 
its specific substrate, which leads to its proteasomal degradation. We were wondering, if we 
were able to stabilize known CRL substrates by overexpressing BPLF-1-N. By knowing that 
BPLF1 is a nuclear protein expressed in the early phase of the productive virus cycle, we 
assumed an involvement of the protein in DNA replication. Several CRL regulated substrates 
are involved in cell cycle control, like the licensing factor CDT1, the tumor suppressor p21 
and p27 and the cyclin phosphatase cdc 25c. All those proteins are targeted by Cul1 and/or 
Cul4 based CRLs. Expression of those CRL substrates together with BPLF1-N lead to their 
stabilisation detected via Western blot. The accumulation of those cell cycle regulators was 
reversed in a dose dependent manner by overexpression of V5-NEDD8, whereas a mutant 
V5-NEDD8-VV, lacking the C-terminal Gly residue required for conjugation, and HA-
ubiquitin had minor or no effects. As described in earlier chapters, viral modulation of CRLs 
is a common mechanism to control pathways essential for the virus life cycle, like viral 
replication or hiding from the immune surveillance. Several DNA viruses, like HPV (75), 
Adenovirus (76), SV40 (79) and now also due to our studies EBV, have been described to 
manipulate CRLs to insure their undisturbed genome replication.  
After overexpression of BPLF1-N in various eukaryotic cell types it could be shown, that the 
enzyme localises predominately to the nucleus, detected via immunofluorescence. The effect 
of this nuclear accumulation of BPLF1-N was an increased size of the nucleus and on 
prolonged expression, extensive cell death. Those detected effects were not due its 
overexpression but due its catalytic activity, because a catalytic inactive mutant, BPLF1-N 
C61A missed to establish this phenotype. To investigate the cause of the nuclear enlargement, 
BPLF1-N transfected cells were stained with propidium iodide, a fluorescent agent, which 
binds to DNA. After this treatment the cell cycle profile and DNA content was assessed of 
those cells. Taken together the compiled results of those experiments indicated a deregulation 
of the S-phase and an ongoing re-replication of cellular DNA without mitosis 
(endoreduplication). Almost all BPLF1-N expressing cells died within 4-5 days. This 
phenotype was reversed in a dose-dependent manner by overexpression of NEDD8 but not by 
overexpression of ubiquitin. This result suggests that BPLF1-N´s deneddylase activity rather 
then its DUB activity seems to be responsible for this phenotype.  
Further BPLF1-N overexpression experiments in different eukaryotic cell lines elucidated the 
stabilisation of several CRL substrates or activation of certain regulator proteins, essential for 
DNA synthesis and cell cycle progressing. To summarize, the composition of those activated 
or stabilised proteins also represents our earlier detected cell cycle milieu of an S-phase like 
environment and endoreduplication in BPLF1-N expressing cells (see for details publication 
II). Among those stabilised proteins was the DNA licensing factor CDT1 (chromatin licensing 
and DNA replication factor 1). CDT1 functions as a regulatory protein of the pre-RC (pre-
replication complex), which is essential for the initiation of DNA replication. The pre-RC 
binds to the oriP (origin of replication) and “licenses” the initiation of replication during the 
S-phase. Cdt1 is tightly regulated through ubiquitin-dependent proteolysis facilitated by Cul1 
and Cul4 based CRLs. The involvement of the cellular DNA replication machinery in 
replication of the viral genome is poorly understood for the HHV-family.  
To elucidate whether the detected S-phase like environment and endoreduplication in BPLF1-
N expressing cells has an impact of viral replication we used the Akata-Bx1 cell line. This B-
cell lymphoma cell line carries a recombinant EBV genome within, which can be induced to 
start its lytic cycle by crosslinking of cell surface immunoglobulins. Entrance into the viral 
replication state can be visualised by the expression of a viral early protein substituted with 
GFP (green fluorescent protein). EBV replication in those cells causes the same phenotype as 
in BPLF1-N overexpressed cell lines, an S-phase like environment and endoreduplication, 
detected via cell cycle diagram assays.  
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Also in those EBV reactivated cells the same milieu of activated or CRL stabilised proteins 
essential for DNA synthesis and cell cycle progressing was detected as in BPLF1-N 
expressing cells. Among them also the stabilised Cul1 and Cul4 based CRL target CDT1. 
Upon silencing BPLF1 expression in those induced Akata cells via the transduction of shRNA 
(short hairpin RNA) against BPLF1 mRNA, the normal cell cycle diagram could be 
reconstituted. After overexpression of CDT1 in those BPLF1 knock downed cells, the 
BPLF1-N detected S-phase like phenotype could be reconstituted to a certain extend. This 
result demonstrates the big impact of the BPLF1-N stabilized CRL substrate CDT1. It also 
indicates the essential involvement of probably other stabilized CRL substrates to reconstitute 
the BPLF1-N overexpression phenotype.  
In order to investigate the impact of BPLF1 expression towards viral genome replication, we 
assayed the viral DNA contend in BPLF1 knock down induced Akata cells via RTq-PCR (real 
time quantitative-PCR). The knock down of BPLF1 resulted in an almost complete inhibition 
of virus DNA replication. Thereafter, we also wanted to investigate the impact of 
overexpressed CDT1 in BPLF1 knock downed, induced Akata cells. Overexpression of CDT1 
in those cells let to reactivation of viral replication to an almost full degree. To summaries this 
data demonstrates that stabilisation of CDT1 is critical for the introduction of an S-phase-like 
cellular environment, and the driving factor for viral replication. 
 
To investigate whether BPLF1-N´s deneddylase activity and caused induction of cellular 
DNA re-replication are conserved among the HHV-family, we tested the BPLF1 homologues 
UL36 of HSV and M48 of MCMV. GST fusions of the N-termini of UL36 and M48 cleaved 
the Ub-GFP and NEDD8-GFP reporter constructs with comparable efficiency in the above 
explained bacterial screening assay. Also Flag tagged UL36-N and M48-N reacted with the 
Ub-VS and NEDD8-VS suicidal probes as described earlier for Flag-BPLF1-N. 
Overexpression of Flag-UL36-N and Flag-M48-N also introduced an S-phase cellular 
environment and endoreduplication, as seen after Flag-BPLF1-N expression. Taken together, 
those results suggest that the function of BPLF1 is conserved among members of the HHV-
family.    
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4.  ONGOING RESEARCH AND FUTURE PERSPECTIVES 
 
 
In previous experiments we could show, that BPLF1-N was able to bind to Cul1 and Cul4a. In 
order to address the question, if BPLF1-N was able to bind to the whole cullin family, we 
overexpressed all Myc-tagged cullins (Cul-1,-2,-3,-4a,-4b,-5) together with Flag-BPLF1-N in 
eukaryotic cells. In following we performed Co-IP experiments with Flag- and Myc- 
antibodies and were able to Co-IP Flag-BPLF1 with all Myc-cullins and also all Myc-cullins 
with Flag-BPLF1. These results indicate that CRLs comprised of the entire cullin family may 
be target of BPLF1-N.  
We were also interested to investigate on which cullin domain BPLF1-N binding occurs and 
if the binding is direct or if cellular adaptors are involved. To address this question we 
generated different GST tagged Cul4a domains. In following pull-down assays with 
eukaryotic cell lysates containing overexpressed Flag-BPLF1-N, we could identify its site of 
interaction towards the cullin C-terminus, closely located to the neddylation site. In order to 
investigate, if cellular adaptors are involved in this binding, the experiment was repeated with 
bacterial expressed and purified His-BPLF1-N. Also this attempt resulted in binding of 
BPLF1-N to the same C-terminal located Cul4a domain, showing that this interaction is direct 
and no cellular adaptors are involved.  
In order to elucidate the BPLF1-N residues involved in binding towards cullins, in silico 
sequence alignments among all human virus homologues of BPLF1_N were conducted. The 
alignment result revealed a conserved α-helical structure located on the enzymes surface. A 
high degree on conservation was detected on two charged residues Asp86 and Asp90 pointing 
outwards of this α-helix. After mutating those two residues into opposite charged residues 
Asp86Arg and Asp90Arg the interaction of Flag-BPLF1_D86R_D90R towards Myc-Cul1 
and Myc-Cul4a could be reduced to ∼90%, detected via Co-IP experiments. To insure that 
this degrease in binding was not due possible structural changes caused by the mutation, the 
conserved α- helical structure containing Asp86 and Asp90 were cloned into a bacterial His-
expression vector. In following the same mutations D86R_D90R were applied on this 
BPLF1-N helical fragment and pull down assays were conducted with GST-Cul4a. The result 
was showing again a ∼90% reduction in binding compared to the wild type BPLF1-N helical 
fragment. The outcome of those binding experiments strongly suggests that the two conserved 
residues Asp86 and Asp90 located within the conserved α- helical structure are the essential 
residues involved in the interaction towards Cul1 and Cul4a and possibly to all cullins. 
  
As in publication II shown, overexpression of BPLF1-N induces a cellular S-phase like 
environment and leads to endoreduplication. As we could show, this phenotype was caused 
by BPLF1`s ability to bind to cullins and its impact to stabilize CRL substrates. In future 
experiments the cell cycle analysis will be repeated with the binding mutant 
BPLF1_D86R_D90R. If we would detect a strong degrease or an absence of the described 
BPLF1-N phenotype, we would have an additional strong argument for the capacity of 
BPLF1 to bind to cullins and its ability to stabilise CRL substrates. 
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Manipulation of the ubiquitin proteasome system (UPS) is emerging as a common theme in viral patho-
genesis. Some viruses have been shown to encode functional homologs of UPS enzymes, suggesting that a
systematic identification of these products may provide new insights into virus-host cell interactions. Ubiq-
uitin-specific proteases, collectively known as deubiquitinating enzymes (DUBs), regulate the activity of the
UPS by hydrolyzing ubiquitin peptide or isopeptide bonds. The prediction of viral DUBs based on sequence
similarity with known enzymes is hampered by the diversity of viral genomes. In this study sequence align-
ments, pattern searches, and hidden Markov models were developed for the conserved C- and H-boxes of the
known DUB families and used to search the open reading frames (ORFs) of Epstein-Barr virus (EBV), a large
gammaherpesvirus that has been implicated in the pathogenesis of a broad spectrum of human malignancies
of lymphoid and epithelial cell origin. The searches identified a limited number of EBV ORFs that contain
putative DUB catalytic domains. DUB activity was confirmed by functional assays and mutation analysis for
three high scoring candidates, supporting the usefulness of this bioinformatics approach in predicting distant
homologues of cellular enzymes.
The posttranslational modification of proteins by ubiquitin
(Ub) and Ub-like molecules (UbLs) and the degradation of
polyubiquitinated substrates by the proteasome regulate fun-
damental cellular processes, including cell growth and differ-
entiation, intracellular signaling, protein trafficking, apoptosis,
and the recognition of virus-infected or malignant cells by the
host immune response (21, 27, 33, 44, 46). Modulation of the
ubiquitin-proteasome system (UPS) is emerging as a central
theme in viral pathogenesis, and several examples have been
reported of viral proteins that mimic or redirect the activity of
the system in order to modify the cellular environment in favor
of virus persistence or replication (22, 28, 31, 34, 41, 45). Thus,
the identification of viral products that interfere with the UPS
may yield new insights on important features of viral patho-
genesis and could lead to the development of new means of
therapeutic intervention.
Conjugation of Ub or UbLs is achieved through the activity
of a cascade of enzymes, including activating enzymes (E1s),
conjugating enzymes (E2s), and specific ligases (E3s) that cat-
alyze the covalent linkage of the modifier to Lys residues in the
substrate (11). In addition, deconjugating enzymes act as reg-
ulators of the system by maintaining the pool of free Ub and
UbLs and by determining the rate of turnover of the conju-
gates (14, 50). In line with this proposed regulatory function,
recent evidence points to a critical role of Ub deconjugases
(deubiquitinating enzymes [DUBs]) in intracellular signaling,
as exemplified by the activation of the transcription factor
nuclear factor-B (NF-B) by cylindomatosis tumor suppres-
sor, A20, Cezanne, and ubiquitin-specific protease 31 (25, 33)
and by the initiation of DNA repair by USP1 (37).
Based on similarity with known family members, the human
DUBs have been classified in five subfamilies including: ubiq-
uitin C-terminal hydrolases (UCHs), ubiquitin-specific pro-
teases (USPs), Machado-Joseph disease proteases (MJDs or
Josephins), ovarian tumor proteases (otubains, OTUs), and
the JAMM (Jab1/MPN/Mov34 metalloenzyme) motif pro-
teases (2, 38). With the exception of JAMMs, the DUBs are
cysteine proteases identified by a catalytic triad of Cys, His,
and Asp/Asn residues and by the presence of conserved amino
acid domains known as Cys- and His-boxes (C- and H-boxes,
respectively) that are unique for each family (38). Mutational
studies have shown that the Asp/Asn residue is not essential
for catalytic activity, although it may contribute to the enzy-
matic activity by stabilizing the active-site thiolate and imid-
azolium ion pair (26, 35). The JAMM metalloproteases lack a
C-box, while two conserved His residues in the JAMM motif
were shown to be essential for activity (49).
Proteins with DUB activity are encoded in the genome of
human adenovirus, herpesvirus, coronavirus, and bunyavirus
(5, 6, 18, 29, 42). Furthermore, DUB activity was recently
demonstrated in proteins encoded by some pathogenic bacte-
ria that lack an intrinsic UPS (40, 52), suggesting that these
enzymes play specific roles in the regulation of both viral and
bacterial infection. Although these findings make the system-
atic identification of microbial DUBs a worthy endeavor, the
task is complicated by the wide sequence variation of the
known enzymes. Moreover, viral and bacterial proteins are
often considerably different in sequence and domain organi-
zation compared to their mammalian counterparts, which fur-
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ther hampers the identification of distant functional homo-
logues.
We have used a bioinformatics strategy here to identify
putative virus-encoded DUBs. To overcome the difficulty
posed by sequence variation, we focused on the conserved C-
and H-boxes. Family-specific sequence alignments, pattern
searches, and hidden Markov models (HMMs) were generated
based on the amino acid sequences of known members of the
five DUB subfamilies and then used to search a custom-made
database of open reading frames (ORFs) from Epstein-Barr
virus (EBV), a human gamma herpesvirus that establishes la-
tent infections and is associated with a broad spectrum of
malignancies of lymphoid and epithelial cell origin.
MATERIALS AND METHODS
Data sets. The sequences of DUBs were extracted from the UniProt database
version 51.2 (4). The DUB data set consisted of both experimentally verified
human enzymes and highly conserved sequence homologs (Table 1). For families
with fewer than 10 human sequences, homologues from other species were
included. The sequence of the B95.8 EBV genome (3) was obtained from NCBI
GenBank (Refseq NC_007605). The sequences of 75 annotated EBV ORFs were
retrieved from the Swiss-Prot database. In addition, ORF prediction was carried
out with the getORF program available in the EMBOSS package (39), with a
length cutoff setting between 150 and 5,000 amino acids (aa), which resulted in
106 predicted ORFs. For ORFs annotated in Swiss-Prot, the progressive number
assigned to the predicted ORFs was substituted with the corresponding gene
symbol.
DUB searches. (i) Sequence alignment. Sequence comparisons between the
human DUBs and the EBV ORFs were carried out by using CLUSTAL W (47)
and BLAST (1). CLUSTAL W calculates multiple sequence alignments and was
therefore used to investigate whether any of the EBV ORFs clusters with the
specific DUB subfamilies. BLAST searches were used to identify putative C- and
H-boxes. To this end, members of each DUB family were aligned by using
CLUSTAL W, and conserved catalytic domains were extracted with the GoCore
program (http://www.helsinki.fi/project/ritvos/GoCore/). The C- and H-box do-
mains of each family were defined on the basis of the conserved regions (UCH,
C-box 23aa and H-box 24aa; USP, C-box 16aa and H-Box 21aa; OTU, C-box
19aa and H-box 14aa; MJD, C-box 21aa and H-box 14aa; JAMM domain 25aa),
and the sequences were then searched against the EBV ORF database. Hits with
arbitrarily chosen E-values of 10 and containing Cys or His residues were
selected for further analysis.
(ii) Pattern search. C- and H-box specific patterns were constructed to search
for putative catalytic domains. The C- and H-boxes of each DUB family were
aligned with respect to the conserved Cys and His residues, and search patterns
were manually derived from the sequence alignments based on the physicochem-
ical properties.
(iii) HMM search. HMMs were constructed by using the HMMER (17) suite
of programs. For each DUB subfamily the HMMs were trained with multiple
sequence alignments of C- and H-boxes from a nonredundant set of sequences
(Table 1, HMM training set). The HMM results were further categorized
based on E-values and raw scores. In every search with subfamily-specific
HMMs, matches with E-values of 25 were selected and manually screened
for the presence of Cys or His residues in the alignment. Candidates con-
taining putative C- or H-boxes were further categorized based on the HMM
scores of the domains. The HMM score is a base 2 log of the probability of
alignment to the HMM divided by the probability of random alignment. A
score of zero represents 50% likelihood that the sequence is a true match to
the model. Since the EBV ORF database contains 106 entries, scores greater
than 6.7 correspond to a 99% probability to detect true homologs while a
score of 6.6 corresponds to 1% probability. Due to the fact that the ge-
nomes of viral and other pathogenic organisms undergo higher mutation rates
(16), low thresholds of statistical parameters were used to detect catalytic
domains of DUBs.
(iv) Conserved Cys and His residue search. Homologous proteins that are
conserved between members of at least one subfamily of human herpesviruses
(-HHVs: herpes simplex virus type 1 [HSV-1], HHV1, HSV-2, HHV2, varicel-
la-zoster virus, and HHV3; -HHVs: human cytomegalovirus, HHV5, HHV6,
HHV7; and -HHVs: EBV, HHV4, Kaposi sarcoma herpesvirus, and HHV8)
were identified by using BLAST with a cutoff E-value of 0.01, corresponding 99%
probability to be a true homolog. Homologous proteins were then aligned by
using Vector NTI (32), and the multiple alignments of each cluster were scanned
for the presence of conserved Cys and His residues. Sequences flanking the
conserved residues were searched for putative C- and H-boxes using the
HMMs.
Functional validation of candidate DUBs: cloning of EBV ORFs into prokary-
otic expression vector. ORFs derived from the B95-8 virus were transferred from
the GATEWAY expression vector pDONR207 (48) to the prokaryotic expres-
sion vector pDEST-GST (ampicillin resistance), and E. coli DH5 was used for
transformation.
Ub-GFP construct. Green fluorescent protein (GFP) was amplified by PCR
from pEGFP-N1 vector (Clontech, Palo Alto, CA) with the sense primer
5-GTTTTCAGATCTAAAGGAGAAGAGCTGTTCACCGGCGTGAGCA
AGGGCGAGGAGCTGTTCACC-3 and the antisense primer 5-GTTCTC
GAGCTTGTACAGCTCGTCCATGCCGAGAGTGAT-3 and cloned in the
BglII and XhoI sites of the pACYCDuet-1 vector (Novagen, Darmstadt,
Germany). Ubiquitin was amplified by PCR from an Ub-Gal plasmid with
the primer 5-GTTGAATTCAATGCAAATCTTCGTGAAGACTCTGACT
GGTA-3 and the antisense primer 5-GTTAGATCTGAACCCACCTCTG
AGACGGAGTACCA-3 and inserted in frame in the EcoRI and BglII sites
of the pACYCDuet-1 vector containing GFP. The underlined sequences
represent restriction sites.
DUB assays. The GST-ORFs and Ub-GFP reporter plasmids were cotrans-
fected by electroporation in competent BL21(DE3) bacteria that lack endoge-
nous DUBs (9). Antibiotic-resistant colonies were selected in LB agar supplied
with 100 	g of ampicillin/ml and 30 mg of chloramphenicol/ml. Exponentially
growing bacteria (OD at 600 nm of 0.5) were induced for 5 h at 30°C with 0.5 mM
IPTG (isopropyl--D-thiogalactopyranoside) and then lysed by sonication in
phosphate-buffered saline supplemented with protease inhibitors (Complete
Mini protease inhibitor cocktail tablets; Roche, Germany). The lysates were
clarified by centrifugation for 10 min at 13,000 rpm, and cleavage of the reporter
was analyzed by fractionation in acrylamide bis-Tris 4 to 12% precasted gradient
gel (Invitrogen), followed by Western blotting. After transfer to polyvinylidene
difluoride membrane (Millipore), the filter was blocked in phosphate-buffered
saline supplemented with 5% nonfat milk and 0.1% Tween 20 and incubated for
1 h with anti-rabbit-GFP serum (Abcam, Cambridge, United Kingdom) diluted
TABLE 1. Data sets of DUBs used in this study
Protein family Characteristic domain No. of humanDUBs
No. of verified
DUBsa
No. of
orthologs
No. of DUBs
in pattern
search setb
No. of DUBs in
HMM training setd
C-box H-box
USP Peptidase 19 45 37 45 36 42
UCHL Peptidase 12 4 4 15 19 10 8
OTU OTU 8 5 9 17 10 11
MJD Josephin 3 1 9 12 7 7
JAMMc MPN 8 2 29 34 21
a That is, the number of DUBs with experimentally verified enzymatic activity.
b Due to the small number of identified sequences in the human UCH, OTU, JAMM, and MJD subfamilies, orthologs from other species were included in the
data set.
c The JAMM metalloproteases contain only H-box domains, and sequence homologs with catalytic. His residues were considered for deriving the patterns.
d Only C- and H-boxes with 90% sequence identity were used for training the HMMs.
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1:10,000. After incubation for 1 h with peroxidase-conjugated goat anti-rabbit
serum, the complexes were visualized by enhanced chemiluminescence (GE
Healthcare, United Kingdom). For the enzyme kinetic assays, GST-USP19,
GST-USP19mut, GST-BPLF1-N, GST-BSLF1, and GST-BXLF1 were purified
from bacteria lysates (50 mM Tris-Cl [pH 7.5], 150 mM NaCl, 5 mM MgCl2, 1%
Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol) by
incubation for 90 min at 4°C with a solution of 10 mM glutathione in 50 mM
Tris-Cl (pH 8.0), and the protein concentrations were determined with a Bio-
Rad protein assay. Hydrolysis of the fluorogenic substrate ubiquitin-AMC (Ub-
AMC, SE211; Biomol) was assayed at 30°C in 100 	l of assay buffer (50 mM
Tris-Cl [pH 7.5], 150 mM NaCl, 2 mM EDTA, 2 mM dithiothreitol) containing
200 nM concentrations of the enzyme, and the Vmax and Km of the reactions were
calculated by titrating the substrate at concentrations ranging between 0 and 20
mM. The fluorescent product was measured by using a spectrofluorimetry plate
reader at 380-nm excitation and 460-nm emission wavelengths. To block the
DUB activity, 10 mM N-ethylmaleimide (NEM; Sigma) was added to the assay
buffer.
Site-directed mutagenesis. Point mutations of the predicted catalytic Cys res-
idues of BPLF1, BSLF1, and BXLF1 genes were engineered by using a
QuikChange site-directed mutagenesis kit according to the manufacturer’s pro-
tocol (Stratagene). Two BPLF1 mutants (C61A and C65A), three single mutants
(C462A, C824A, and C819A), and one double mutant (C824/819A) of BSLF1
and two mutants of BXLF1 (C84A and C491A) were constructed. All constructs
were then sequenced to verify that only the desired mutations had been intro-
duced.
RESULTS
Four search strategies were used to identify putative DUBs
encoded in the EBV genome: (i) sequence alignment with the
conserved C- and H-boxes of known DUB families, (ii) pattern
search of conserved catalytic domains, (iii) HMM-based
searches, and (iv) identification of Cys and His residues that
are conserved in homologues encoded by other members of
the HHV family, followed by an HMM search.
Sequence alignment searches. A first attempt to identify
putative DUBs was performed using CLUSTAL W to align the
EBV ORFs with the human DUB data set. Three ORFs clus-
tered with specific DUB subfamilies, BGLF4 and BBLF4 clus-
tered with the OTU subfamily and BcLF1 ORF aligned with
JAMMs (not shown), but the homologous regions did not
contain Cys or His residues, and these viral ORFs are there-
fore unlikely to possess enzymatic activity. Since alignment of
the entire amino acid sequence may not detect homology re-
stricted to short domains that are critical for enzymatic activity,
BLAST was used to identify EBV ORFs containing sequences
of homology with the conserved C- and H-boxes of each DUB
family using an arbitrary cutoff E-value of 10. Twenty-five
candidates containing Cys or His residues in homologous re-
gions were found in this search (see Table S1 in the supple-
mental material), including for example, the BBRF3 ORF that
contains a region of strict homology with the USP C-box (E-
value 
 0.018).
Pattern search. Additional search strategies were conducted
to achieve a more stringent assessment of the likelihood that
the identified domains might be true C- or H-boxes homo-
logues. Family-specific search patterns were derived from the
aligned C- and H-box sequences of the known DUBs. To
increase the stringency of the search, when fewer than 10
family members were found in the human data set, homo-
logues from other species were also included in the alignment.
The derivation of search patterns for the C- and H-boxes of the
UCH family is illustrated in Fig. 1, and the search patterns for
USP, OTU, MJD and JAMM families are given in Fig. S1A to
D in the supplemental material. In a first attempt, stringent
search patterns were derived for each DUB family (UCH,
C-box 11/11 and H-box 7/16; USP, C-box 8/7 and
H-box17/3; OTU, C-box8/10 and H-box8/5; MJD,
C-box 10/10 and H-box 6/7; and JAMM motif 7/17)
by including at each position all residues observed in the data
set (Fig. 1B, boldface residues) and then used to search the
EBV ORF data set, allowing for only a single mismatch. The
derived patterns were in all cases able to identify the DUBs
belonging to the family but failed to identify any candidate in
the EBV ORFs (results not shown), suggesting that they may
be too stringent to recognize distant homologues. Less-strin-
gent search patterns were then derived by allowing at each
position additional amino acids with similar physicochemical
characteristics or, when residues with different physicochemi-
cal characteristics were observed, all amino acids (indicated by
an “X” in Fig. 1B and in Fig. S1A to D in the supplemental
material). Regions of similarity with the C- and/or H-boxes of
different DUB families were identified in 30 EBV ORFs (see
Table S2 in the supplemental material). Four ORFs contained
at least one putative C-box and one H-box, while three ORFs
contained only one putative C-box and twenty-three ORFs
contained one or more H-box-like domain.
HMM search. Family-specific HMMs were derived for the
aligned C- and H-boxes of the different DUB families. In order
to increase the probability of identifying distant homologs, only
sequences with90% identity were included in the training set
(Table 1). Since the EBV ORF database contains only 106
sequences and the HMMs are based on short C- and H-box
domains of 13 to 24 aa, high E-values and low scores were
expected. HMM alignments with E-values of 25 were there-
fore considered for further analysis. All hits containing Cys or
His residues were further categorized based on the HMM
scores (Table 2). Scores of 0, corresponding to more than
50% likelihood to be a true match, were considered high.
Intermediate scores were between 0 and 6.6 (down to 1%
probability to be a true match), while scores less than 6.6
were considered low. Seven EBV ORFs—BALF2, BALF5,
BBRF3, BcLF1, BERF3-BERF4, BRLF1, and the predicted
ORF88—contained at least one C- or H-box domain with
score above 0, suggesting a potential homology with the
corresponding DUB domains. Two ORFs—BNRF1 and
BPLF1—contained both C- and H-box-like domains with
scores 6.6, and eighteen additional ORFs contained either
a C- or an H-box-like domain with scores of less than 6.6.
Search for conserved Cys and His residues. A further at-
tempt to identify candidate DUBs was undertaken based on
the assumption that amino acid residues that are critical for
protein function may be conserved in homologues encoded by
different members of the HHV family. Homologous ORFs
encoded by the known HHVs were identified by sequence
comparison, and the conserved Cys and His residues were
located. Twenty-one EBV ORFs contain at least one Cys or
His residue that is conserved in homologues encoded by all
HHV members, while Cys or His residues conserved only in -
or -HHVs were detected in two and seven ORFs, respec-
tively; thirteen EBV ORFs shared conserved Cys or His resi-
dues only with homologues encoded by the other member of
the -HHV subfamily, KSHV, that resembles EBV in cell
tropism and oncogenic capacity (see Table S3 in the supple-
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mental material). The sequences adjacent to the conserved
residue were searched for putative C- and H-boxes using the
DUB family specific HMMs. Nine EBV ORFs were found to
contain conserved Cys or His residues located in regions ho-
mologous to the DUB C- or H-boxes, and one ORF, BGRF1/
BDRF1, contained both C- and H-box homologous domains
(see Table S3 in the supplemental material).
DUB score and exclusion criteria. A relatively large number
of candidate DUBs were identified by at least one search, and
several were identified by more than one. To select the most
likely candidates for functional studies, scoring criteria were
devised for each search, and these were then compiled in a
global DUB score. The scores assigned to each search reflected
the likelihood of identifying candidates that possess critical
features associated with DUB activity (see Table S4 in the
supplemental material). Candidates identified by the BLAST
search were given a score of 1, 2, or 3 depending on the degree
of similarity with DUB sequences. Candidates identified by the
pattern search were scored 1 or 2 based on the presence of C-
or H-box-like domains or both, while the score of candidates
identified by the HMM considered both the presence of C- and
H-box-like domain and their HMM scores (high 
 0, inter-
mediate 
 between 0 and 6.6, or low 
 6.6). The same
scoring system was used for candidates identified by the pres-
ence of conserved Cys and His residues. The scores of 58
candidates identified by at least one search are shown in Table
S4 in the supplemental material. Two ORFs—BGRF1/BDRF1
and BPLF1—were identified by the four searches, nine ORFs
were identified by three searches, twenty-two ORFs were iden-
tified by two searches, and twenty-five ORFs were found by
only one search. All candidates identified in at least three
searches and five candidates identified by two searches re-
ceived scores of4. This group included 16 ORFs, all of which
were identified by HMM, and 7 were shown to contain con-
served Cys or His residues.
In order to further restrict the number of candidates to be
validated by functional studies, ORFs with scores of 4 were
scrutinized for the presence of structural constraints that could
prevent DUB activity. The locations of the putative C- and
H-boxes were mapped relative to each other and to other
protein domains of known function (Fig. 2). Based on this
domain analysis, the BBRF3 and BILF1 ORFs could be ex-
cluded since their putative C- and H-boxes are located in
transmembrane regions, which would preclude DUB activity.
Analysis of the site of expression in EBV-infected cells, ex-
pression during different phases of the virus cycle, and func-
tional annotation (Table 3) revealed that some of the high-
scoring candidates are structural proteins or glycoproteins
associated with the virus capsid and envelope. These proteins
are unlikely to possess enzymatic activity, although this cannot
be excluded a priori. The remaining candidates include imme-
diate-early, early, late, or latent proteins that are expressed in
FIG. 1. Derivation of search patterns for the UCH subfamily catalytic domains. (A) The aligned amino acid sequences of the catalytic Cys and
His-box regions of UCH (peptidase C12) family members are shown. The numbers above the alignment correspond to the amino acid position
relative to the catalytic Cys and His residues. Polar residues are colored blue, hydrophobic residues are gray, and small residues (Gly and Ala) are
white. (B) Stringent search patterns were derived by including at each position all amino acids observed in the aligned DUB sequences (indicated
in bold). Less-stringent patterns were then obtained by allowing amino acids with similar physicochemical properties (indicated in italics). When
different types of amino acids were observed at a given position, all amino acids were allowed in the pattern (indicated by X).
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the nucleus or, in one case, in the cytoplasm of the infected
cells or are components of the viral tegument. It is noteworthy
that two tegument proteins were found in the group with the
highest DUB score and one of them, the protein encoded by
the BPLF1 ORF, was previously shown to possess DUB activ-
ity (23, 42).
Functional validation of the candidates. In order to validate
the DUB score, GST fusions of 11 EBV ORFs with scores of
4 and an approximately equal number of ORFs with scores
of 3 were tested for their capacity to hydrolyze a Ub-GFP
reporter plasmid coexpressed in bacteria. The results of a rep-
resentative assay wherein the ORFs were tested alongside the
human USP19 and a catalytic mutant that lacks enzymatic
activity are shown in Fig. 3.
The reporter was efficiently cleaved by USP19, as confirmed
by the detection of both free GFP (Fig. 3A) and free ubiquitin
(data not shown), while cleavage was abolished by mutation of
the catalytic Cys residue in the USP19Mut. In line with the
reported DUB activity of this ORF, Ub-GFP was cleaved al-
most completely in bacteria expressing the N terminus of
BPLF1 (Fig. 3A and B). The levels of cleavage significantly
above background were also detected with BSLF1 and BXLF1,
while the activity of BGRF1 and BALF5 was just below the
cutoff (3 the mean percent cleavage in the presence of ORFs
with scores3 [Fig. 3B]). The expression of the fusion proteins
was in all cases confirmed in Western blots probed with anti-
GST antibodies (data not shown). In order to further charac-
terize their DUB activity, bacterially expressed GST-BPLF1-N,
GST-BSLF1, and GST-BXLF1 were purified, and their en-
zyme activity was assayed by cleavage of the fluorogenic sub-
strate Ub-AMC (Fig. 3C). The three EBV ORFs hydrolyzed
Ub-AMC with different kinetics and Km values, suggesting very
different affinities for the substrate, but the specificity of the
reaction was in all cases confirmed by blocking with the cys-
teine protease inhibitor NEM. Interestingly, the enzymatic ac-
tivity of BSLF1 and BXLF1 relative to BPLF1 was significantly
improved when equal amounts of immunoprecipitated pro-
teins expressed in mammalian cells were compared for the
cleavage of Ub-AMC (compare Fig. 3C and D), suggesting that
posttranslational modifications that are not achieved in bacte-
ria cells may be required for optimal activity.
In order to further validate the DUB activity of the candi-
dates, the predicted catalytic Cys residues in BPLF1, BSLF1,
and BXLF1 were mutated to Ala by using PCR-mediated
site-directed mutagenesis, and the enzymatic activity of recom-
binant GST tagged proteins was tested against the Ub-AMC
substrate (Fig. 4). Two putative C-boxes were predicted in the
BSLF1 and BXLF1 ORFs, while a single domain containing
two Cys residues was predicted in BPLF1. Alignment of the
corresponding sequences in other members of the HHV family
revealed that, while BPLF1 Cys61 and BSLF1 Cys819 and
Cys824 are conserved in all HHVs, other potentially catalytic
Cys residues identified by the bioinformatics search are unique
for EBV or shared only by some of the family members. Mu-
tation of the conserved C61 of BPLF1 to Ala abolished the
enzymatic activity, while the C65A mutation had no effect,
confirming that C61 is the catalytic residue in the C-box (Fig.
4). Single mutation of the nonconserved C462 and conserved
C824 of BSLF1 did not affect the enzymatic activity, while the
activity of the C819A mutant was significantly reduced. Inter-
estingly, the hydrolysis of Ub-AMC was further decreased in
the double mutant C819/824A, suggesting that C824 may partly
substitute for the catalytic C819 residue. Homologs of BXLF1
were present only in alpha- and gammaherpesviruses, and the
putative catalytic cysteine C491 is conserved only in gamma-
herpesvirus. Mutation of this residue abolished the enzymatic
activity of BXLF1, while mutation of the nonconserved C84
had no effect (Fig. 4). Thus, catalytic Cys residues were iden-
TABLE 2. Putative DUB catalytic boxes identified by the
HMM searcha
EBV ORF
C-box H-box
Type Score Type Score
BALF1 OTU -0.4
BALF2 OTU 1.9
UCH –6.4
BALF4 OTU –10.2 UCH –9.3
BALF5 USP 0.3
BaRF1 UCH –1.9
BBLF2 USP –2.9
BBLF4 MJD –15 OTU –4.3
BBRF2 USP –3.7
BBRF3 USP 7.8 OTU –6.7
UCH –9.8
BcLF1 OTU 1.3 OTU –4.2
USP –8.4
BcRF1 MJD –9.5
BDLF2 OTU –7.6
BERF3-BERF4 USP 0.69
OTU –7.9
MJD –8.3
BFRF2 OTU –6.8
BGLF1 OTU –1.6 OTU –7.7
BGLF2 OTU –4.6
BGLF3 OTU –5.3
BGRF1/BDRF1 MJD –10.9 MJD –8.1
BILF1 USP –0.6
BKRF1 USP –3
BLLF3 OTU –7.9
BMLF1 OTU –6.7
BMRF2 MJD –9.2
BNRF1 USP –3.9 OTU –2
UCH –9.1
BORF1 USP –4.2
BPLF1 USP –4.5 OTU –4.3
BRLF1 USP 0.9 OTU –6.3
OTU –4.4
BSLF1 OTU –7.8 OTU –6.8
BVRF2 USP –3.5 JAMM –16.2
BXLF1 USP –3.4 USP –13.2
BXLF2 USP –5.2
UCH –5.5
MJD –7.4
BXRF1 MJD –8.9
LMP1 MJD –8.4
LMP2 USP –1
ORF101 USP –2.5
ORF35 OTU –5.3
MJD –7.6
ORF42 OTU –9.6
ORF86 OTU –2.3
USP –4.5
ORF88 OTU –11.1 OTU 2.9
a The type of DUB domain found in each candidate is indicated as follows:
USP, ubiquitin-specific protease; OTU, ovarian tumor domain protease; UCH,
ubiquitin C-terminal hydrolase; MJD, Josephin domain protease. Boldfacing
indicates high scores (0); italics indicates intermediate scores (between 0 and
6.6); regular typeface indicates low scores (–6.6)
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tified by mutation analysis in BPLF1, BSLF1, and BXLF1,
confirming that the three EBV ORFs are bona fide viral
DUBs.
To finally validate our bioinformatics approach, the scoring
strategy used to identify BPLF1, BSLF1, and BXLF1 was ap-
plied to their homologues encoded by other human herpesvi-
ruses. All homologs of BPLF1 and BSLF1 received scores of
4, and several scored even higher than the EBV-encoded
protein (Table 4). This is in line with the reported DUB activity
of several BPLF1 homologues. In agreement with the very low
sequence similarity of the BXLF1 homologues expressed in
alpha- and gammaherpesvirus these ORFs received very low
DUB scores, suggesting that this protein may have different
functions in different viruses.
DISCUSSION
In this study we used a bioinformatics approach to identify
distant functional homologues of human ubiquitin deconju-
gases encoded in the EBV genome. This task is complicated by
the great genetic variability of viruses, which results in poor
sequence conservation even between homologous proteins ex-
pressed by different members of the same virus family. Indeed,
currently used bioinformatics tools, such as BLAST searches
FIG. 2. Mapping of the putative C- and H-box domains in ORFs with high DUB scores. The positions of the putative C- and H boxes identified
by the different searches and the Cys and His residues that are conserved in homologues encoded by other HHV family members are indicated.
Putative transmembrane domains were identified by a TMHMM search in the candidate ORFs and are indicated as yellow hexagonal regions. In
BBFR3, BILF1, and ORF88 the C- and/or B-boxes overlap with or flank transmembrane domains.
TABLE 3. ORF annotation and filtering criteria
EBV ORF DUBscorea EBV protein
Homologue Expression in
virus cycle Location Function
b Filter
HSV CMV KSHV
BBRF3 9 Glycoprotein M gM gM gM Late Envelope M (–)
BcLF1 7 Major capsid protein UL19 UL86 ORF25 Late Capsid C –
BALF5 7 DNA pol catalytic subunit UL30 UL54 ORF9 Early Nucleus R
BGRF1/BDRF1 7 DNA packaging, Terminase UL15 UL89 ORF29 Late Nucleus P
BNRF1 6 Major tegument protein ORF75 Late Tegument T
BPLF1 6 Large tegument protein UL36 UL48 ORF64 Late Tegument T
BXLF2 5 gp85, gH homologue UL22 UL75 ORF22 Late Envelope M (–)
ORF35 5 Hypothetical
ORF88 5 Hypothetical –
BALF2 5 ssDNA binding protein UL29 UL57 ORF6 Early Nucleus R
BSLF1 5 Helicase/primase complex UL52 UL70 ORF56 Early Nucleus R
BILF1 4 gp64, constitutive GPCR Early Membrane M (–)
BERF3-BERF4 4 EBNA3C Latent Nucleus L
BaRF1 4 RNase reductase UL40 ORF60 Early Nucleus N
BRLF1 4 Rta, transactivator ORF50 I-Early Nucleus S
BXLF1 4 Thymidine kinase UL23 ORF21 Early Nucleus N
a For the details on the scoring, see Table S4 in the supplemental material.
b Classification of protein based on function: C, capsid; M, membrane protein; N, nucleotide metabolism; L, latency; P, packaging; R, replication; S, signaling,
transactivator, transcription factor; T, tegument.
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or more sophisticated threading programs that use sequence
alignment and protein fold recognition algorithms, fail to de-
tect homologies between known viral and cellular DUBs, sug-
gesting that the structural properties of the viral proteases are
clearly distinct. This was recently confirmed by the crystal
structure of a DUB encoded by the murine gammaherpesvirus
M48 that, based on the arrangement of the active-site residues
and the architecture of the ubiquitin interacting interface, was
classified as the first member of a new class of DUBs (43).
We reasoned that, in spite of strongly divergent sequences, a
higher degree of conservation might be expected in regions
that are important for enzymatic activity. Thus, although the
homology between the catalytically relevant regions of viral
and cellular enzymes falls below the statistically significant
cutoffs used in conventional searches, distant homologues may
be identified using less-stringent search criteria. The human
genome encodes for approximately 95 DUBs subdivided in five
families (38). Although the sequences of individual DUBs vary
widely, the members of each family share a high degree of
homology in regions surrounding conserved Cys and His resi-
dues that form the catalytic core of the enzymes. We therefore
focused on the identification of EBV ORFs containing a re-
gion of homology with the C- and H-boxes of each DUB family
and scored the candidates based on the degree of homology
with the consensus sequences and on the presence of only one
or both types of consensus domains. Four different strategies
based on sequence alignment, pattern search, HMM motifs,
and detection of conserved Cys and His residues in the context
of HMM motifs were used to search for putative C- and H-
boxes. The use of multiple searches provides a distinct advan-
FIG. 3. Functional validation of the candidate DUBs. (A) Representative Western blot illustrating cleavage of the Ub-GFP reporter by a
restricted panel of EBV ORFs. BL21 cells were cotransfected with Ub-GFP, and the indicated ORF and protein expression was induced by
treatment with IPTG. Cell lysates were fractionated on 4 to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gradient gels, and GFP
was detected by Western blotting. Cleavage of the reporter in lysates expressing active DUBs is visualized by appearance of a free GFP band.
(B) Enzymatic activity of candidate EBV DUBs (score  4) and controls (score  3). The intensity of the bands corresponding to the uncleaved
reporter and free GFP was determined by densitometry, and the percent specific cleavage was calculated as follows: intensity of the free GFP band –
background/total GFP (uncleaved  cleaved) – background  100. A cutoff activity value was calculated as 3  the mean percent specific cleavage
in cells expressing ORFs with a score of 3. The mean of three experiments in which all of the ORFs were tested in parallel is shown in the figure.
(C) Time course of Ub-AMC hydrolysis. Ub-AMC (1.2 	M) was mixed with 200 nM concentrations of purified GST-USP19wt, GST-USP19mut,
GST-BPLF1-N, GST-BSLF1, and GST-BXLF1 in the absence (empty symbols) or presence (filled symbols) of NEM, and the reactions were
monitored for 180 min. The release of fluorescent AMC, expressed in arbitrary units (AU), shows the activity of these enzymes to cleave Ub-AMC.
The Km of the reactions was calculated in separate experiments and is indicated in the Figure. (D) Time course of Ub-AMC hydrolysis of BPLF1,
BSLF1, and BXLF1 expressed in mammalian cells. The ORFs were cloned in frame in the 3XFlag tag vector and expressed in HEK293 cells. The
proteins were immunoprecipitated from the transfected cells using antibodies to the Flag tag, and the cleavage of Ub-AMC was assayed as
described for panel C. Equal amounts of proteins were used in all enzymatic assays. The faster kinetics of Ub-AMC cleavage (compare panels C
and D) indicates that the enzymatic activity of mammalian expressed BSLF1 and BXLF1 is significantly improved compared to the proteins
expressed in bacteria.
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tage since each search is biased by different criteria. Thus,
while sequence alignment scores for the presence of a contin-
uous sequence of homologous residues, the pattern search
restricts the hits to sequences that share similar residues at
critical positions in the motif and HMM gives a global score
based on the likelihood that a given residue will be found in
each position of the motif. A further refinement of the HMM
search was based on the assumption that functionally relevant
proteins will be conserved among members of a virus family,
and therefore conserved Cys and His residues will be found in
the putative catalytic domains. By assigning individual scores
to each of these searches and then combining the scores into a
global DUB score, we have identified 16 candidates with DUB
scores of 4 out of 106 annotated or predicted ORF in the
EBV genome. Five of the candidates were excluded from fur-
ther analysis because the putative catalytic domains are located
within or at the opposite sides for transmembrane domains or
because they are either known structural components of the
virus capsid or envelope glycoproteins and are therefore un-
likely to possess DUB activity.
A previously identified viral DUB encoded by the BPLF1
ORF was found among the high score candidates. BPLF1 is
the EBV homologue of UL36, a presumably multifunctional
protein of the alphaherpesvirus HSV-1. DUB activity was pre-
viously mapped to the N-terminal portion of UL36 by using a
functional proteomic approach based on labeling of total cell
extracts with and epitope-tagged, Ub-based suicide substrates
followed by immunoprecipitation, and identification of the la-
beled enzyme by mass spectrometry (23). Using a reporter
substrate that carries ubiquitin fused to GFP in a conformation
that mimics the ubiquitin precursors and, to some extent, a
true ubiquitinated substrate, we have now confirmed that the N
terminus of BPLF1 is a very potent ubiquitin deconjugase.
Interestingly, two additional ORFs in the high-score group,
BSLF1 and BXLF1, were also capable of cleaving Ub-GFP at
levels significantly above background. The enzymatic activity of
FIG. 4. Identification of the catalytic Cys residues by site-directed mutagenesis. Sequence alignments of the putative catalytic C-boxes in
BPLF1, BSLF1, and BXLF1 and their homologs encoded by other HHV members shows conservation of Cys residues that are involved in DUB
activity. The conserved residues are shown in white text with a black background, while similar residues in the alignment are shaded in gray. The
asterisk above the alignment indicates the Cys residues identified in the bioinformatics search. Mutations were introduced into the predicted
catalytic Cys residues, and the ability of the mutants to hydrolyze Ub-AMC was assayed as described in the legend to Fig. 3.
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the new putative DUBs was in both cases confirmed by the
capacity of the purified GST fusion proteins to cleave the
fluorogenic substrate Ub-AMC. Furthermore, the catalytic Cys
residues were identified in both proteins by mutation analysis,
confirming that these EBV ORFs are bona fide DUBs. It is
noteworthy that bacterially expressed full-length BSLF1 and
BXLF1 exhibited a poor enzymatic activity compared to both
the N-terminal portion of BPLF1 and the human DUB USP19
that was included as control. Comparison of the enzymatic
activity of purified proteins expressed in mammalian cells sug-
gests that this may be due to the requirement for posttransla-
tional modifications that are not achieved in bacteria. Indeed,
only the N terminus of UL36 was identified in the functional
screen performed in HSV-1-infected cells, suggesting that the
protein may be processed during infection.
The new viral DUBs identified in the present study are
expressed in the nucleus of EBV-infected cells during the early
phases of the productive virus cycle and, based on their anno-
tated functions, are involved in DNA replication and nucleo-
tide metabolism. It is noteworthy that the efficiency and fidelity
of DNA replication is regulated by posttranslational modifica-
tion of several components of the replication complex, includ-
ing for example, monoubiquitination, polyubiquitination, and
sumoylation of PCNA (36). The BSLF1 gene product shares
23% sequence identity with HSV UL52, the primase compo-
nent of the trimolecular helicase-primase complex was shown
to be essential to HSV replication (12, 13). In EBV the com-
plex is made up of BSLF1, BBLF4 (UL5 homolog), and
BBLF2/3 (UL8 homolog) (51), but its activity in viral replica-
tion has not been directly confirmed. Similar to UL52, BSLF1
contain several conserved amino acid domains, such as the
DxD motif (aa 481 to 498) and a putative zinc finger (Znf; aa
782 to 829) motif at the C-terminal end of protein that are also
found in prokaryotic and eukaryotic primases (7, 15, 24). Mu-
tational analysis of the Znf of HSV UL52 showed that this
region is required for the virus replication (7, 8, 10). The Znf
of BSLF1 partially overlaps with the predicted catalytic C-box.
BXLF1 gene encodes a protein of 607 aa that was annotated
as the EBV thymidine kinase (TK) gene due to its capacity to
complement TK-negative strains of E. coli (30) and partial
sequence homology with regions of HSV-1 TK (19). We found
that the regions that identify BXLF1 as a putative DUB and
the catalytic Cys residue are not conserved in other herpesvirus
homologues. Moreover, in contrast to other family members,
BXLF1 was shown to localize to the centrosomes, where it
encircles the tubulin-rich centrioles in a microtubule-indepen-
dent manner (20). It remains to be seen whether this atypical
localization may reflect a dual enzymatic activity that is not
present in the homologues.
In conclusion, we have shown that it is possible to use bioin-
formatics tools to identify distant homologues of DUBs en-
coded by viruses. Our strategy of choosing candidates based on
a global DUB score obtained by combining the results of mul-
tiple low stringency searches identified 16 high scoring ORFs
in a database of 106 putative or confirmed EBV ORFs. Enzy-
matic activity was confirmed for 3 of 11 ORFs tested, whereas
ORFs with low score and ORFs lacking putative C- or H-boxes
were uniformly negative. Thanks to its relatively good predic-
tive capacity, our approach could provide a valuable comple-
ment to the functional screening described by Kattenhorn et al.
(23), which, due to the requirement for validation by mass
spectroscopy, is strongly biased toward enzymes that are over-
expressed in the infected cells. Further studies will be required
to assess how the DUB activity of BPLF1, BSLF1, and BXL1
contributes to their role in virus replication and to the
remodeling of the cellular environment during productive
EBV infection.
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A deneddylase encoded by Epstein–Barr virus 
promotes viral DNA replication by regulating the activity 
of cullin-RING ligases
Stefano Gastaldello1, Sebastian Hildebrand1, Omid Faridani1, Simone Callegari1, Mia Palmkvist1,  
Claudia Di Guglielmo1 and Maria G. Masucci1,2
The large tegument proteins of herpesviruses encode conserved cysteine proteases of unknown function. Here we show that 
BPLF1, the Epstein–Barr-virus-encoded member of this protease family, is a deneddylase that regulates virus production by 
modulating the activity of cullin-RING ligases (CRLs). BPLF1 hydrolyses NEDD8 conjugates in vitro, acts as a deneddylase in 
vivo, binds to cullins and stabilizes CRL substrates. Expression of BPLF1 alone or in the context of the productive virus cycle 
induces accumulation of the licensing factor CDT1 and deregulates S-phase DNA synthesis. Inhibition of BPLF1 during the 
productive virus cycle prevents cellular DNA re-replication and inhibits virus replication. Viral DNA synthesis is restored by 
overexpression of CDT1. Homologues encoded by other herpesviruses share the deneddylase activity. Thus, these enzymes are 
likely to have a key function in the virus life cycle by inducing a replication-permissive S-phase-like cellular environment.
Post-translational modification of proteins by ubiquitin regulates a mul-
titude of cellular processes involving their turnover, activity, interactions 
and trafficking through cellular compartments1. Ubiquitin conjugation 
is mediated by a cysteine-based enzymatic cascade that comprises an 
ATP-dependent activating enzyme (E1), a conjugating enzyme (E2) and 
a substrate-specific ligase (E3) that transfers the modifier to the acceptor 
protein2. The modification is reversed by deconjugases that hydrolyse 
the covalent bond formed between the modifier and the substrate3. Since 
the discovery of the ubiquitin conjugation system, similar pathways for 
the conjugation of ubiquitin-like proteins (UbLs), including NEDD8, 
ISG15, SUMO-1, SUMO-2, SUMO-3 and others, have been identified4. 
Modification by UbLs does not usually result in protein degradation, 
although important crosstalks have been highlighted by the demonstra-
tion that NEDD8 (ref. 5) and SUMO6,7 regulate the activity of certain 
E3s. Thus, the best-characterized substrates of NEDD8 conjugation are 
cullins that function as scaffolds for the assembly of cullin-RING ligases 
(CRLs)8. Neddylation is required for ligase activity and thereby controls 
the ubiquitylation and kinetics of degradation of CRL substrates9.
Viruses exploit the ubiquitin and UbL signalling cascades in almost 
every step of their life cycle10. In addition, viruses manipulate innate 
and adaptive immune responses that are controlled by these modifica-
tions, including the production of interferons and immunoregulatory 
cytokines and the processing of viral proteins into antigenic peptides11. 
Interference strategies are epitomized by the capacity of viral proteins, 
such as the human papillomavirus E6, to bind cellular E3s and redirect 
their activity towards substrates whose destruction favours virus repli-
cation12. Deconjugases, such as the ubiquitin-specific protease USP7-
HAUSP, are similarly targeted by herpes simplex virus (HSV) ICP0 
(ref. 13) and Epstein–Barr virus (EBV) EBNA-1 (ref. 14) to alter the 
turnover of cellular regulators of DNA synthesis and apoptosis. Viruses 
also encode functional homologues of these enzymes that often share 
little homology with their cellular counterparts and are therefore attrac-
tive targets for selective inhibition15.
EBV is a gammaherpesvirus that immortalizes B lymphocytes and is 
associated with human malignancies16. B-cell immortalization is caused 
by a latent infection in which viral proteins hijack signalling pathways 
controlling cell proliferation, differentiation and apoptosis17. While 
this phase of the virus life cycle is relatively well understood, much less 
is known about virus replication. Virus production is initiated by the 
immediate-early protein BZLF1, which transactivates viral and cellular 
promoters, leading to the sequential expression of genes involved in 
viral DNA synthesis, virus assembly and maturation18. In a similar man-
ner to other herpesviruses, the productive cycle of EBV occurs in an 
S-phase-like cellular environment and activates ATM (ataxia telangiecta-
sia mutated) and Chk2-dependent DNA damage responses19. BZLF1 
induces this phenotype only in EBV-positive cells, suggesting that other 
viral proteins are involved.
With the use of a functional screen based on the co-expression of glu-
tathione S-transferase (GST)-tagged EBV open reading frames (ORFs) 
with green fluorescent protein (GFP)-based ubiquitin and UbL reporters 
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Figure 1 BPLF1 is a NEDD8-specific deconjugase. (a) Screen for 
EBV encoded ubiquitin-specific and UbL-specific deconjugases. A 
library of 88 EBV ORFs was tested for cleavage of ubiquitin–, ISG15–, 
NEDD8–, SUMO-1, SUMO-2, or SUMO-3–GFP–S-tag reporters in 
bacterial assays. Bacterial lysates containing equal GFP fluorescence 
units were fractionated by SDS–PAGE and western blots were probed 
with an S-tag-specific antibody. The percentage specific cleavage was 
calculated as 100 × (intensity of free GFP minus the background)/(total 
GFP intensity minus background). Specific deconjugases for ubiquitin 
= USP19, ISG15 = USP4, NEDD8 = NEDP1, SUMO-1, SUMO-2, 
SUMO-3 = SENP1 were used as positive controls. (b) BPLF1 cleaves 
ubiquitin-AMC (Ub-AMC) and NEDD8-AMC with equal efficiency. The 
indicated purified proteins (50 nM) were mixed with 1.2 µM ubiquitin-
AMC (open symbols) or NEDD8-AMC (filled symbols). Where indicated, 
the enzymatic reaction was carried out in the presence of 10 mM NEM. 
The Km and kcat of the reactions were calculated in two independent 
experiments by titrating the fluorogenic substrates over a fixed amount 
of enzyme. Squares, BPLF1; down triangles, BPLF1C61A; circles, 
NEDP1; diamonds, NEDP1C163S; plus signs, BPLF1 + NEM; up triangles, 
NEDP1 + NEM. The mean ± s.d. of two experiments performed in 
triplicate are shown. (c) BPLF1 cleaves NEDD8 conjugates. V5–NEDD8 
was expressed in HeLa cells, and conjugates were captured on anti-V5-
conjugated Sepharose beads. Equal amounts of beads were mixed with 
200 nM of purified GST, GST–BPLF1 or GST–BPLF1C61A and the reaction 
was run for 1 h at 37 °C. NEDD8 conjugates were detected in western 
blots probed with the anti-V5 antibody. Only the wild-type BPLF1 
hydrolyses NEDD8 conjugates, and the reaction is inhibited by NEM. 
Immunoglobulin heavy and light chains are indicated by asterisks. (d) 
Eukaryotic expressed BPLF1 retains deneddylase activity. The activity of 
Flag–BPLF1 or Flag–BPLF1C61A expressed in HeLa cells was assessed by 
binding of the functional probes ubiquitin-VS and NEDD8-VS. Binding 
was visualized in western blots probed with the anti-Flag antibody as 
a band shift of about 10 kDa, corresponding to the size of the probe. 
(e) BPLF1 hydrolyses NEDD8 conjugates in vivo. V5–NEDD8 was co-
transfected in HeLa cells together with Flag-tagged BPLF1, NEDP1 and 
the catalytic mutants BPLF1C61A and NEDP1C163S. NEDD8 conjugates 
were detected in western blots with the anti-V5 antibody. BPLF1 and 
NEDP1 were detected with the anti-Flag antibody. One representative 
experiment of three is shown. Uncropped images of blots are shown in 
Supplementary Information, Fig. S6.
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we have discovered that the conserved cysteine protease encoded in the 
amino terminus of major tegument protein BPLF1 is a deneddylase that 
binds to cullins and regulates the activity of CRLs, leading to deregula-
tion of the cell cycle. Inhibition of BPLF1 during the productive cycle 
severely diminishes the yield of viral DNA.
RESuLTS
The N terminus of BPLF1 encodes a NEDD8-specific deconjugase
In search for EBV-encoded ubiquitin or UbL deconjugases we used a 
bacterial assay20 in which plasmids encoding GST-tagged EBV ORFs 
were co-expressed together with reporter plasmids encoding GFP fused 
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Figure 2 BPLF1 deneddylates cullins and induces the accumulation of 
CRL substrates. Myc-tagged Cul1 and Cul4A were co-expressed in HeLa 
cells together with Flag-tagged BPLF1, NEDP1 or BPLF1C61A, and co-
immunoprecipitations were performed with anti-Myc or anti-Flag antibodies. (a) 
BPLF1 induces cullin deneddylation. Neddylated cullins were detected in blots 
probed with an anti-Myc antibody as a minor slowly migrating species (upper 
panel, indicated by arrowheads), and the identity of the bands was confirmed 
by re-probing with an anti-V5 antibody (lower panel). IP, immunoprecipitation. 
(b) BPLF1 binds to cullins. Cell lysates of HeLa cells co-transfected with 
Myc-tagged Cul1 or Cul4A and Flag-tagged BPLF1, NEDP1 or BPLF1C61A were 
immunoprecipitated with anti-Myc (upper panels) or anti-Flag (lower panels) 
antibodies and western blots were sequentially probed with anti-Myc and anti-
Flag antibodies. Both cullins were co-immunoprecipitated by the wild-type and 
mutant BPLF1, whereas only a weak interaction was detected with NEDP1 
(indicated by asterisks). Omission of the cysteine protease inhibitor NEM from 
the lysis buffer (–) did not affect the efficiency of co-immunoprecipitation of 
cullin with BPLF1. (c) BPLF1 binds to endogenously expressed cullins. Cul4A 
and BPLF1 were immunoprecipitated from lysates of HeLa cells transfected 
with Flag alone, Flag–BPLF1 or Flag–BPLF1C61A using specific antibodies, and 
western blots were sequentially probed with antibodies against Cul4A, Flag and 
c-Myc. One representative experiment of three is shown. (d) Expression of the 
CRL substrates CDT1, Cdc25A, p27 and p21 was assayed in HeLa cells 48 h 
after transfection with BPLF1 or a control empty vector. The accumulation of 
CRL substrates in BPLF1-expressing cells was reversed in a dose-dependent 
manner by overexpression of NEDD8, whereas a mutant V5–NEDD8-VV, 
lacking the C-terminal Gly residue required for conjugation, and HA–ubiquitin 
had minor or no effects. One representative experiment of three is shown. 
Uncropped images of blots are shown in Supplementary Information, Fig. S6.
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to either ubiquitin, ISG15, NEDD8, SUMO-1, SUMO-2 or SUMO-3. 
Cleavage of the reporters was assessed in western blots by the appear-
ance of free GFP (Supplementary Information, Fig. S1). Representative 
assays in which the ORF library was tested against each reporter along-
side appropriate controls are shown in Fig. 1a. Ubiquitin–GFP and 
NEDD8–GFP were cleaved almost completely by a construct encoding 
the N-terminal 325 amino-acid residues of the major tegument protein 
BPLF1 (hereafter termed BPLF1). Additional ORFs showed inefficient 
cleavage of these reporters, and none cleaved the ISG15, SUMO-1, 
SUMO-2 and SUMO-3 reporters. 
The N terminus of BPLF1 encodes the EBV homologue of a conserved 
herpesvirus cysteine protease21. Because other members of this family 
had been shown to act preferentially as ubiquitin-specific proteases, we 
first examined whether BPLF1 is a true deneddylase. The activity of 
purified GST–BPLF1 against the fluorogenic substrates ubiquitin-AMC 
(where AMC is 7-amino-4-methylcoumarin) and NEDD8-AMC was 
tested alongside a mutant in which the catalytic Cys 61 was replaced 
by Ala (BPLF1C61A), the NEDD8-specific protease NEDP1 (ref. 22) and 
its catalytic mutant NEDP1C163S. Ubiquitin-AMC and NEDD8-AMC 
were hydrolysed by BPLF1, whereas NEDP1 hydrolysed only NEDD8-
AMC, as expected. BPLF1 and NEDP1 showed comparable Km and kcat 
values for NEDD8-AMC, suggesting similar affinities for the substrate 
(Fig. 1b). Hydrolysis was abrogated by the cysteine protease inhibitor 
N-ethylmaleimide (NEM) and by mutation of the catalytic cysteine. To 
test whether BPLF1 can hydrolyse true NEDD8 conjugates, a V5-tagged 
NEDD8 was expressed in HeLa cells and conjugates were captured on 
anti-V5-Sepharose beads. Equal amounts of beads were incubated with 
purified GST–BPLF1 in the presence or absence of NEM or, as controls, 
with purified GST and GST–BPLF1C61A (Fig. 1c).  Only wild-type BPLF1 
hydrolysed the NEDD8 conjugates as detected in western blots probed 
with the anti-V5 antibody. As expected, ubiquitin conjugates were also 
cleaved (Supplementary Information, Fig. S2).
Having confirmed the capacity of recombinant BPLF1 to act as a 
deneddylase in vitro we examined whether the activity is retained by 
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Figure 3 Expression of a catalytically active BPLF1 induces accumulation 
of cells with a DNA content of at least 4N. HeLa cells were transfected with 
Flag–BPLF1 and Flag–BPLF1C61A, and subcellular localization and cell cycle 
profile were assayed after 48 h. (a) The subcellular localization of the BPLF1 
was detected by immunofluorescence with an anti-Flag antibody (red signal), 
cytoskeletal actin was revealed by staining with fluorescein isothiocyanate 
(FITC)-labelled phalloidin (green signal), and cellular nuclei were stained 
with 4,6-diamidino-2-phenylindole (DAPI). Both the wild-type and catalytic 
mutant BPLF1 accumulate in the nucleus but only the catalytically active 
enzyme induces a significant increase in nuclear size. Scale bars, 5 µm. 
Nuclear size was measured with the ImageJ software in 30 randomly 
selected nuclei from each experimental condition. One representative 
experiment of three is shown. Three asterisks, P = 0.002. (b) The cell cycle 
profiles of mock-transfected cells (control) and of cells transfected with 
the wild-type and catalytic mutant BPLF1 were assessed by staining with 
PI 48 h after transfection. Expression of the catalytically active BPLF1 was 
accompanied by the accumulation of cells with a DNA content of at least 
4N. The table shows the percentages of apoptotic cells (less than 2N) and 
cells in G1 (2N) and S-G2 (4N) and cell with more than 4N DNA content 
(means ± s.d.) in three independent experiments. (c) The re-replication 
phenotype induced by BPLF1 is counteracted in a dose-dependent manner 
by overexpression of NEDD8. HeLa cells were co-transfected with 2 µg 
of a plasmid expressing the catalytically active BPLF1 (+) and increasing 
amounts of plasmids expressing either V5–NEDD8 or HA–ubiquitin. The cell 
cycle profile was analysed by staining with PI 48 h after transfection. The 
percentage of cells with DNA content of more than 4N is indicated in each 
panel. Overexpression of NEDD8 or ubiquitin alone had no effect on the cell 
cycle profile. One representative experiment of three is shown.
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eukaryotic-expressed BPLF1. Lysates of HeLa cells expressing Flag–
BPLF1 and Flag–BPLF1C61A were labelled with the functional probes 
ubiquitin-VS and NEDD8-VS (where VS is 3-vinyl-(methyl)-sulphone), 
which form covalent adducts with the catalytic cysteine residue23. As 
illustrated in Fig. 1d, in which activity is revealed by a shift of the specific 
band corresponding to the size of the probe, BPLF1 bound ubiquitin 
and NEDD8 with comparable efficiency over a wide range of concentra-
tions, whereas binding was abolished in the catalytic mutant. We finally 
tested whether BPLF1 acts as a deneddylase in vivo. Flag-tagged BPLF1, 
NEDP1 and their catalytic mutants were co-transfected in HeLa cells 
together with V5–NEDD8, and the presence of conjugates was assayed in 
western blots with the anti-V5 antibody (Fig. 1e). A comparable decrease 
in NEDD8 adducts was observed in cells expressing BPLF1 and NEDP1, 
whereas the catalytic mutants had no effect. Taken together, these data 
demonstrate that the N terminus of the EBV major tegument protein 
BPLF1 encodes a cysteine protease with specificity for NEDD8 conju-
gates in vitro and in vivo. 
BPLF1 binds to cullins and inhibits the activity of CRLs
Cullins are the best-characterized substrates of NEDD8 conjugation. 
We therefore examined whether BPLF1 acts as a cullin deneddylase. 
Myc-tagged versions of two representative members of this family, Cul1 
and Cul4A, were co-transfected in HeLa cells together with V5–NEDD8 
and Flag–BPLF1, Flag–BPLF1C61A or Flag–NEDP1. Cell lysates were 
immunoprecipitated with an anti-Myc antibody, and western blots were 
probed sequentially with anti-Myc and anti-V5 antibodies (Fig. 2a). 
Slowly migrating species corresponding to neddylated cullins, con-
firmed by reactivity with the anti-V5 antibody (Fig. 2a, lower panel), 
were detected when the proteins were expressed alone or together with 
BPLF1C61A, whereas the neddylated species disappeared in the presence 
of BPLF1 and NEDP1.
To investigate whether the enzymes interact with their substrates, 
lysates of HeLa cells co-transfected with Myc-tagged cullins and Flag-
tagged enzymes were immunoprecipitated with the anti-Myc or anti-
Flag antibodies. Sequential probing of western blots revealed a strong 
interaction of BPLF1 with both cullins, whereas NEDP1 interacted only 
very weakly (minor co-precipitated species are indicated by asterisks in 
Fig. 2b). The interaction of BPLF1 with cullins was independent of its 
catalytic activity and was not affected by the omission of NEM from the 
lysis buffer, suggesting that it does not involve binding to NEDD8. To 
test whether BPLF1 also interacts with endogenously expressed cullins, 
Cul4A was immunoprecipitated from lysates of HeLa cells transfected 
with Flag-vector, Flag–BPLF1 and Flag–BPLF1C61A, and western blots 
were sequentially probed with anti-Flag, anti-Cul4A and, as control, 
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Figure 4 Cell cycle deregulation in cells expressing BPLF1. Total cell 
lysates from HeLa cells transfected with empty vector (control), BPLF1 or 
BPLF1C61A were fractionated by SDS–PAGE and western blots were probed 
sequentially with the indicated antibodies. Expression of the catalytically 
active BPLF1 was associated with an accumulation of E2F1, cyclin E 
and cyclin A, indicating entry into S phase; increased levels of pCdc6 
and CDT1 and decreased levels of the CDT1 inhibitor geminin suggesting 
re-licensing of replication origins; failure to activate the ATR kinase and 
its downstream target Chk1 and accumulation of Cdc25A suggesting 
failure to activate the intera-S-phase checkpoint; accumulation of pATM, 
pChk2 and phosphorylated H2AX (pH2AX) indicating induction of DNA 
damage and activation of the G2 checkpoint; failure to accumulate 
phosphohistone H3 (pH3) indicating that the cells are not progressing 
into mitosis. Results from one representative experiment of three 
are shown. Uncropped images of blots are shown in Supplementary 
Information, Fig. S6.
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anti-Myc antibodies (Fig. 2c). Both the active and catalytic mutant 
BPLF1 were detected in the immunoprecipitates, whereas c-Myc was 
not, confirming the specificity of the interaction.
Because neddylation activates CRLs we then asked whether BPLF1 
modulates the activity of CRLs in vivo. Flag–BPLF1 and Flag–BPLF1C61A 
were transfected in HeLa cells and the expression of CDT1 (CRL4-
DDB1CDT2 and CRL1Skp2 substrate24), Cdc25A (CRL1βTrCP substrate25), 
p21 and p27 (CRL1Skp2 substrates26) was assayed in western blots. Strong 
accumulation was observed in cells expressing the active enzyme 
(Fig. 2d) but not in those expressing the catalytic mutant (Supplementary 
Information, Fig. S3). This was reversed in a dose-dependent manner 
by co-expression of V5–NEDD8, in parallel with reconstitution of 
cullin neddylation (Fig. 2d). A V5–NEDD8-VV mutant that lacks the 
carboxy-terminal Gly residue required for conjugation had some effect 
only at the highest plasmid concentrations when faint cullin–NEDD8 
bands were also detected, whereas haemagglutinin (HA)-tagged ubiq-
uitin had no effect.
BPLF1 deregulates S-phase DNA synthesis
The binding to cullins and selective inhibition by overexpression of 
NEDD8 are consistent with the possibility that BPLF1 may act as a 
deneddylase in vivo. This was investigated by expressing BPLF1 in a 
range of cell types. The wild-type and mutant BPLF1 showed a pre-
dominant nuclear localization in transfected HeLa cells (Fig. 3a) and in 
other cell lines tested, including HEK293 and Chinese hamster ovary (not 
shown). The active enzyme induced a marked increase in the size of the 
nucleus (Fig. 3a, lower panel) and, on prolonged expression, extensive 
cell death. To explore the cause of nuclear enlargement, the cell cycle 
profile and DNA content were assessed by staining with propidium iodide 
(PI; Fig. 3b). Expression of BPLF1 was associated with a decrease in the 
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Figure 5 Activation of the EBV productive cycle is associated with cellular 
DNA re-replication. The productive virus cycle was induced in Akata-Bx1 
cells by treatment with anti-human IgG antibodies and revealed by 
GFP fluorescence. (a) Activation of the productive cycle induces the 
accumulation of cells with a DNA content of 4N or more. DNA content 
was analysed by staining with PI in EBV-negative Akata and Akata-Bx1 
cells treated with the anti-IgG antibody for 72 h. (b) Time-dependent 
accumulation of cells with a DNA content of 4N or more: the percentage 
of cells with this DNA content was measured over time in Akata cells 
(circles) and Akata-Bx1 cells (triangles) either untreated (filled symbols) or 
treated with anti-IgG antibodies (open symbols). Almost all live Akata-Bx1 
cells showed a DNA content of 4N or more within 72 h of treatment. One 
representative experiment of three is shown. (c) Inhibition of EBV DNA 
replication by treatment with the viral polymerase inhibitor Foscarnet. EBV 
DNA content was assessed by qPCR in Akata-Bx1 cells treated for 72 h 
with anti-IgG alone (control) or in the presence of 50 µM Foscarnet. A more 
than tenfold increase in viral DNA was detected by qPCR specific for unique 
sequences in the genes encoding BZLF1 and EBNA-1 in the control anti-
IgG-treated Akata-Bx1 calls, whereas viral DNA replication was abolished 
in the presence of Foscarnet. Results are shown as means and s.d. for two 
experiments performed in triplicate. (d) Treatment with Foscarnet does not 
affect the accumulation of cells with a DNA content of 4N or more. DNA 
content was assessed by staining with PI in Akata-Bx1 cells treated with 
anti-IgG for 72 h in the presence or absence of 50 µM Foscarnet. One out 
of two representative experiments is shown. (e) Induction of the productive 
virus cycle is associated with cellular S-phase defects. Cell lysates of 
untreated Akata-Bx1 cells and cells treated with anti-IgG for 72 h were 
fractionated by SDS–PAGE, and western blots were probed sequentially 
with the indicated antibodies. Uncropped images of blots are shown in 
Supplementary Information, Fig. S6.
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number of cells in G1 stage and an increase in cells with a DNA content 
of 4N or more. More than 80% of the transfected cells showed a DNA 
content of 4N or more within 48 h, and the remaining cells showed signs 
of apoptosis (DNA content less than 2N; Fig. 3b, lower panel). Almost all 
the BPLF1-expressing cells were dead within 4–5 days after transfection. 
This phenotype was reversed in a dose-dependent manner by overexpres-
sion of NEDD8 but not by overexpression of ubiquitin (Fig. 3c).
The accumulation of cells with a DNA content of 4N or more sug-
gests that BPLF1 may cause deregulation of the S phase and re-repli-
cation of cellular DNA. Consistent with this possibility, expression of 
the active enzyme was associated with accumulation of the CRL1Skp2 
substrate E2F1 (ref. 27) and its downstream targets cyclin E and cyc-
lin A (Fig. 4). Furthermore, phosphorylated Cdc6 and CDT1 were 
increased, whereas the CDT1 inhibitor geminin was decreased, sug-
gesting enhanced licensing of DNA replication origins. DNA re-repli-
cation induces DNA damage and elicits DNA-damage responses that 
halt progression of the cell cycle28. DNA damage was revealed by the 
accumulation of phosphorylated histone H2AX. However, the ATR 
(ataxia telangiectasia and rad-3-related) kinase and its downstream 
target Chk1 were not phosphorylated, and Cdc25A, which is targeted 
for degradation after phosphorylation by Chk1 (ref. 25), was strongly 
stabilized, suggesting failure of the intra-S-phase checkpoint29. 
Enhanced phosphorylation of ATM and its downstream targets Chk2 
indicated activation of the G2 checkpoint30, whereas the failure to 
accumulate phosphohistone H3 confirmed that BPLF1-expressing 
cells did not undergo transition into mitosis31. Taken together, these 
findings indicate that BPLF1 induces DNA re-replication, which cor-
relates with the stabilization of several CRL substrates that regulate 
DNA synthesis and cell cycle progression.
BPLF1 is required for efficient EBV DNA replication
The contribution of the cellular DNA replication machinery to herpes-
virus replication is poorly understood. To assess whether the pseudo-S-
phase induced by BPLF1 has any function, we used the Akata-Bx1 cell 
line, which carries a recombinant EBV in which the thymidine kinase 
gene has been replaced with GFP32. The productive virus cycle is induced 
in Akata-Bx1 cells by the crosslinking of surface immunoglobulins, which 
mimics the physiological trigger of EBV replication occurring in vivo33. 
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Figure 6 Expression of BPLF1 is required for efficient EBV DNA replication. 
Akata-Bx1 cells were infected with recombinant lentivirus expressing a 
scrambled shRNA (shScr) or shRNAs specific for the EBV immediate-early 
protein BZLF1 (shBZ1) or BPLF1 (shBP1). After 48 h, half of the infected 
cells were treated with anti-IgG antibodies to induce the productive cycle. 
(a) Total cell lysates were fractionated by SDS–PAGE, and western blots 
were probed with antibodies specific for the EBV transactivator BZLF1, the 
early antigen BORF2 (ribonucleotide diphosphate reductase involved in viral 
DNA replication) and late antigen gp220/350 (viral envelope glycoprotein). 
Antibodies against the EBV latent antigen EBNA-1 and against actin (not 
shown) were used as loading controls. Expression of early and late products 
of the EBV replicative cycle was inhibited by shRNA knockdown of BZLF1, 
whereas knockdown of BPLF1 had no effect. One representative experiment 
of three is shown. (b) Expression of BPLF1 is required for cellular DNA 
re-replication in cells entering the productive virus cycle. The efficiency 
of entry into the productive cycle (GFP fluorescence) and DNA content 
(staining with PI) were monitored in Akata-Bx1 cells and in Akata-Bx1 cells 
infected with the indicated recombinant lentiviruses. BZLF1 knockdown 
prevented both entry into the productive virus cycle and accumulation 
of cells with a DNA content of 4N or more, whereas BPLF1 knockdown 
selectively abolished cellular DNA re-replication. The percentage of cells 
with a DNA content of more than 4N is indicated in each panel. (c) qPCR 
analysis of EBV DNA content was performed in anti-IgG-treated Akata-Bx1 
cells infected with the indicated recombinant lentiviruses. Comparable 
inhibition of EBV DNA replication was achieved by knockdown of BZLF1 
and BPLF1. Results are shown as means and s.d. for  three experiments 
each performed in triplicate. Uncropped images of blots are shown in 
Supplementary Information, Fig. S6.
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We first examined whether the productive virus cycle is associated with 
cellular DNA re-replication. EBV-negative Akata and Akata-Bx1 cells 
were treated with anti-IgG, followed by monitoring of virus reactivation 
and cell cycle distribution by GFP fluorescence and staining with PI. 
Treatment with anti-IgG did not affect the cell cycle in Akata cells, whereas 
EBV reactivation was accompanied by a marked increase in the number 
of cells with a DNA content of 4N or more in Akata-Bx1 cells (Fig. 5a), 
reaching more than 80% of the live cell population within 72 h (Fig. 5b). 
To exclude a possible contribution of newly synthesized viral DNA, the 
anti-IgG treatment was repeated in the presence of the herpesvirus DNA 
polymerase inhibitor Foscarnet34. Treatment with Foscarnet abolished EBV 
DNA replication (Fig. 5c) but did not affect the re-replication of cellular 
DNA (Fig. 5d). Furthermore, induction of the productive virus cycle was 
accompanied by the accumulation of CDT1, pATM, pH 2AX and Cdc25A 
and a failure to accumulate phosphohistone H3 (Fig. 5e).
Although BPLF1 is a virion component, expression of the messenger 
RNA was detected by quantitative polymerase chain reactions (qPCRs) 
specific for the N-terminal and C-terminal domains of the tran-
script within few hours after triggering by anti-IgG (Supplementary 
Information, Fig. S4). This kinetics of expression is reminiscent of 
that of early genes that are induced by BZLF1 and mediate replication 
of the EBV genome35. To test whether BPLF1 regulates EBV repli-
cation, its expression was inhibited by transducing anti-IgG-treated 
Akata-Bx1 cells with recombinant lentiviruses expressing specific 
short hairpin RNAs (shRNAs) (shBP1) and, as controls, shRNAs to 
BZLF1 (shBZ1) or a scrambled shRNA (Supplementary Information, 
Fig. S5). The scrambled shRNA did not affect EBV reactivation as 
detected by expression of the immediate-early protein BZLF1, the 
early protein BORF2 and the late proteins gp220–350, whereas full 
inhibition was achieved by BZLF1 knockdown, as expected (Fig. 6a). 
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Figure 7 Overexpression of CDT1 promotes EBV DNA replication. (a) BPLF1 
knockdown prevents the accumulation of the licensing factor CDT1 in cells 
entering the productive virus cycle. Expression of CDT1 was investigated in 
western blots of control and anti-IgG-treated Akata-Bx1 cells infected with 
the indicated recombinant lentiviruses. CDT1 did not accumulate when 
entry into the productive virus cycle was inhibited by BZLF1 knockdown, 
and similar inhibition was achieved by knockdown of BPLF1. CDT1 levels 
were quantified by densitometry of western blots from three independent 
experiments; the histogram shows fold increases in CDT1 (means and s.d.). 
(b) CDT1 overexpression reconstitutes cellular DNA re-replication in BPLF1 
knockdown cells. Induction of productive virus cycle (GFP fluorescence) 
and DNA content (staining with PI) were monitored in anti-IgG-treated 
Akata-Bx1 cells with or without infection with the indicated lentiviruses. 
Cells transduced with the shBP1 lentivirus were transfected with a CDT1 
expression vector, and expression of the transfected gene was confirmed 
by western blots. (c) overexpression of CDT1 reconstitutes EBV DNA 
replication. The amount of viral DNA was quantified in control and anti-
IgG-treated Akata-Bx1 cells by qPCR with primers specific for BZLF1 
and EBNA-1. Overexpression of CDT1 (lower panel) did not affect EBV 
DNA replication in cells transduced with the control scrambled shRNA 
lentivirus and did not promote virus replication in the absence of BZLF1, 
whereas viral DNA replication was reconstituted by overexpression of 
CDT1 in cells transduced with the shBP1 lentivirus. The fold increases in 
DNA content are shown as means and s.d. for two experiments performed 
in triplicate. Uncropped images of blots are shown in Supplementary 
Information, Fig. S6.
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The expression of viral proteins was not affected by BPLF1 knock-
down (Fig. 6a). However, the accumulation of cells with a DNA con-
tent of 4N or more was abrogated (Fig. 6b), which was correlated 
with an almost complete inhibition of virus DNA replication (Fig. 6c). 
Thus, BPLF1 seems to act downstream of BZLF1 to promote efficient 
replication of the EBV genome.
EBV replication is dependent on overexpression of CDT1
We then sought to identify which among the cellular products 
regulated by BPLF1 is required for EBV DNA replication. Because 
overexpression of CDT1 causes cellular DNA re-replication36, we 
tested whether BPLF1 is required for the accumulation of CDT1 
in cells entering the productive virus cycle. Transduction of anti-
IgG-treated Akata-Bx1 cells with the shBZ1 lentivirus abolished the 
accumulation of CDT1; a comparable inhibition was observed with 
the shBP1 lentivirus, confirming that BPLF1 regulates the abun-
dance of this CRL substrate during productive infection (Fig. 7a). 
Overexpression of CDT1 partly reconstituted the cellular DNA re-
replication phenotype induced by BPLF1 knockdown (Fig. 7b). Most 
significantly, although overexpression of CDT1 did not affect EBV 
DNA replication either alone or in the absence of BZLF1 (Fig. 7c), 
it reconstituted virus production in BPLF1 knockdown cells. Taken 
together, these data demonstrate that stabilization of CDT1 is critical 
for the induction of an S-phase-like environment that is permissive 
of virus replication.
Deneddylase activity of BPLF1 homologues
We finally tested whether the deneddylase activity and induction of 
cellular DNA re-replication are conserved among BPLF1 homologues 
encoded by other herpesviruses. GST fusions of the N termini of 
HSV-UL36 and MCMV-M48 were assayed for cleavage of the ubiqui-
tin/UbL–GFP reporters in bacteria co-expression assays. The ubiquitin 
and NEDD8 reporters were cleaved with comparable efficiency (Fig. 8a). 
Furthermore, Flag-tagged viral proteins retained the capacity to bind 
NEDD8-VS when expressed in HeLa cells (Fig. 8b), and overexpression 
was associated with an accumulation of cells with a DNA content of 
4N or more, comparable to that achieved by overexpression of BPLF1 
(Fig. 8c). Thus, both deneddylase activity and S-phase deregulation seem 
to be conserved in this family of viral enzymes.
DISCuSSIoN
Pathogenic viruses and intracellular bacteria have evolved elaborate 
strategies for manipulating the ubiquitin and UbL signalling machin-
eries, including the production of functional homologues of cellu-
lar enzymes. Here we discovered that a conserved cysteine protease 
encoded in the N terminus of the major tegument protein of herpers-
viridae acts in vivo as a NEDD8-specific protease that binds to cullins 
and regulates the turnover of CRL substrates. Expression of this viral 
deneddylase is associated with deregulation of the cell cycle and with 
the establishment of an S-phase-like environment that is required for 
efficient replication of the viral genome.
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Figure 8 Deneddylase activity is shared by BPLF1 homologues encoded 
by other herpesviruses. (a) GST-fusion chimaeras of the N-terminal EBV-
BPLF1 (amino-acid residues 1–325), HSV-UL36 (residues 1–290) and 
MCMV-M48 (residues 1–315) were tested for cleavage of the ubiquitin–GFP 
and ubiquitin-NEDD8 reporters as described in the legend to Fig. 1a. One 
representative experiment of three is shown. (b) Eukaryotic expressed 
proteins retain deneddylase activity. Flag-tagged BPLF1, HSV-UL36 
and MCMV-M48 were expressed in HeLa cells, and enzymatic activity 
was assayed by labelling with ubiquitin-VS and increasing amounts of 
NEDD8-VS. Binding of the probes was detected in western blots probed 
with the anti-Flag antibody. (c) The cell cycle profile of HeLa cells 
transfected with wild-type and catalytic mutant BPLF1, HSV-UL36 or 
MCMV-M48 was assessed by staining with PI 48 h after transfection. 
Expression of the active enzymes induced a comparable accumulation of 
cells with a DNA content of 4N or more. The percentage of cells with a 
DNA content of 4N or more is indicated in each panel. One representative 
experiment of three is shown. Uncropped images of blots are shown in 
Supplementary Information, Fig. S6.
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On the basis of in vitro assays performed with fluorogenic substrates, 
branched peptides and functional probes, it was suggested that UL36, the 
HSV1-encoded founding member of this family of viral enzymes, and other 
homologues including BPLF1, preferentially cleave ubiquitin adducts21. Our 
data confirm the capacity of EBV-BPLF1, HSV-UL36 and MCMV-M48 
to cleave ubiquitin conjugates but demonstrate that they cleave NEDD8 
adducts with comparable efficiency (Fig. 8). Most significantly, we have 
shown that BPLF1 is capable of hydrolysing true NEDD8 conjugates in 
vitro and in transfected cells (Fig. 1). Given the high degree of homology 
between ubiquitin and NEDD8 this dual specificity is not surprising and is 
indeed shared by many ubiquitin-specific proteases3. It is noteworthy that 
the exquisite specificity of NEDP1 for NEDD8 adducts was attributed to 
the presence of bulky residues in the catalytic cleft that restrict the access 
of ubiquitin37. The large Arg 72 residue in the C terminus of ubiquitin is 
replaced by Ala in NEDD8, which may allow accommodation of the slen-
der C terminus into a broader range of catalytic clefts. On the basis of the 
crystal structure of MCMV-M48 crosslinked to ubiquitin-vinylmethyl ester 
(VME) it was proposed that a hydrogen bond between Arg 72 and Thr 80 
in MCMV-M48 may be crucial for the binding of ubiquitin, and lack of 
this interaction was implicated in the failure to bind NEDD8-VME38. We 
have used a different NEDD8 probe, namely NEDD8-VS. Conceivably, the 
presence of a glycine-VS reactive group, rather than glycine-VME, could 
explain the different reactivity of MCMV-M48. Indeed, previous reports 
have documented differences in the crosslinking efficiency of various ubiq-
uitin functional probes, including failure of ubiquitin-VME to recognize 
the ubiquitin protease OTUB1 (ref. 39).
Although the double specificity of BPLF1 for both ubiquitin and 
NEDD8 was documented in a range of in vitro assays, several lines of 
evidence suggest that the deneddylase activity may have a dominant 
function in vivo. BPLF1 binds to and deneddylates cullins and induces 
the stabilization of several CRL substrates. The capacity to interact 
tightly with cullins is a unique feature of BPLF1 and, together with its 
nuclear localization, suggests that the enzyme may specifically target 
this group of NEDD8 substrates. The finding that stabilization of CRL 
substrates, such as CDT1, Cdc25A, p21 and p27, was efficiently coun-
teracted by overexpression of NEDD8 but not that of NEDD8-VV or 
ubiquitin further supports the key role of cullin deneddylation. Although 
both ubiquitin and NEDD8 are abundantly expressed in cells, the effect 
of NEDD8 overexpression indicates that the neddylation cycle may be 
tightly regulated and may be critically dependent on local concentrations 
of the modifier. Most significantly, the phenotype of BPLF1 overexpres-
sion is consistent with the selective stabilization of CRL substrates that 
control DNA replication and cell cycle progression. A very similar phe-
notype is induced in cells treated with MLN4924, a potent inhibitor of 
the NEDD8-activating enzyme that inactivates the conjugation cascade40. 
A surprising difference between the effect of BPLF1 and MLN4924 is the 
failure to activate ATR and Chk1 in BPLF1-expressing cells. The mecha-
nisms of this selectivity are unclear but may reflect the capacity of the 
viral enzyme to interact preferentially with a distinct subset of NEDD8 
substrates in vivo. Thus, although a contributory effect of deubiquit-
ylation is possible, our findings strongly indicate that the deneddylase 
activity and the specific targeting to cullins are decisive for the effect of 
BPLF1 in transfected cells and during EBV reactivation.
The strict human tropism of EBV does not allow a direct assessment 
of the contribution of BPLF1 to viral infection in vivo. However, evi-
dence from animal herpesviruses confirms that the enzymatic activity 
of this protein family is important in viral pathogenesis by regulating 
the yield of infectious virus. Thus, mutations of the catalytic cysteine 
residue in ORF64 of murine gammaherpesvirus-68 and pUL36 of 
pseudorabies virus (suid herpesvirus 1) yielded viruses that replicate 
less efficiently in vitro and are less pathogenic in vivo41,42, whereas a 
mutation that inactivates the homologue encoded by Marek’s disease 
virus was shown to diminish replication in vivo and severely limit the 
oncogenic potential of the virus43. Our finding that BPLF1, and by 
inference other homologues, regulates the efficiency of virus replica-
tion by contributing to the establishment of an S-phase-like environ-
ment provides a new insight into the still poorly understood process 
of herpesvirus replication. Although increasing evidence implicates 
viral proteins in the deregulation of the host cell cycle that accompa-
nies viral DNA synthesis, the mechanisms and possible contribution 
of cellular factors remain largely unknown44. Notably, although all the 
components of the DNA polymerases of herpesviruses are known, the 
reconstituted enzymes are poorly active in vitro, suggesting that cel-
lular processivity factors may be missing45. Our finding that BPLF1 
promotes EBV DNA replication by stabilizing CDT1 points to this and 
possibly other components of the cellular DNA-replication licensing 
machinery as likely candidates. 
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Antibodies. The following antibodies were used: anti-S-tag (71549-3, 1:6000, 
Novagen, Darmstadt, Germany); anti-V5 (R960-25, 1:2500, Invitrogen, Carlsbad, 
CA); anti-β-actin and anti-Flag (AC-15 1:5000, F-3165 1:8000, Sigma, St Louis, MO); 
anti-p27/Kip1 and anti-human IgG (M7203 1:1000, A0423 1:50, DAKO, Denmark); 
anti-p21/Cip1/WAF1 (610233 1:1000, BD Biosciences); anti EBV EA-R (BORF2, 
sc-56979 1:1000), BZLF1 (sc-53094 1:1000), ATR (sc-28091 1:1000), E2F-1 (sc-251 
1:1000), geminin (sc-13015 1:1000), cyclin-E (sc-20684 1:1000), cyclin-A (sc-751 
1:1000), cyclin-B1 (sc-245 1:1000), Cdt1 (sc-28262 1:1000), p53 (sc-126 1:1000), 
c-Myc (sc-40 1:3000), Cdc25A (sc-7157 1:1000), phospho-Cdc6-S54 (sc-12970-R 
1:1000) from Santa Cruz Biotechnogy, Santa Cruz CA; anti-retinoblastoma (Rb) 
(SA-124 1:1000, Enzo, Life Sciences, PA); anti-phospho-Chk2-T68, phospho-
Chk1-S345 1:1000, phospho-ATR-S428, anti-phospho-H3-S10 1:1000 all from Cell 
Signalling, Danvers, MA; anti-phospho-ATM-S1981 (NB100-306 1:1000, Novus 
Biologicals, Littleton, CO); anti-ATM and anti-Cullin4A (ab-34897 1:1000, ab-2618 
1:3000,  AbCam, Cambridge, MA); anti-phospho-H2AX-S139 1:1000 (Millipore 
Corporation, Billerica, MA); anti-EBV gp220/350 1:100 and EBNA1 (OT1-X 1:1000) 
(gifts of Jaap M. Middeldorp, CCA-VUMC, Amsterdam, The Netherlands). 
Plasmids. The GST–BPLF1 (amino-acid residues 1–325) and ubiquitin–GFP 
plasmids were described previously20. The coding sequences of NEDD8, ISG15, 
SUMO-1, SUMO-2 and SUMO-3 were cloned in frame with GFP into the BglII 
and XhoI sites of the GFP–S-tag-pACYCDuet-1 plasmid (Novagen). Bacterial and 
eukaryotic expression plasmids encoding residues 1–290 of HSV1-UL36 and resi-
dues 1–315 of MCMV-M48 were cloned in the pDEST-GST Flag-tag vectors.
Immunoblots. The cells were lysed in buffer (25 mM Tris-HCl pH 7.6, 50 mM 
NaCl, 1 mM EDTA, 0.5% Nonidet P40, 0.1% SDS, 0.5% sodium deoxycholate) 
containing protease inhibitors (Complete Mini Protease Inhibitor Cocktail tab-
lets; Roche) and 10 mM NEM (Sigma), and protein concentration was measured 
with a Protein Assay kit (Bio-Rad Laboratories). Equal amounts of proteins were 
fractionated in a polyacrylamide Bis-Tris 4–12% gradient or in polyacrylamide 
Tris-acetate 7% linear precast gels (Invitrogen). After transfer to poly(vinylidene 
difluoride) membranes (Millipore), the filters were blocked in PBS saline buffer 
containing 5% non-fat milk and 0.1% Tween 20 and incubated with primary 
antibodies either for 1 h at 24°C or overnight at 4 °C followed by incubation for 1 h 
with the appropriate horseradish peroxidase-conjugated secondary antibodies. 
The complexes were revealed by chemiluminescence (ECL; GE Healthcare).
RT-PCR and qPCR. Complementary DNA was synthesized from 1 µg of total 
RNA in 20 µl of buffer containing 200 ng of Random Primers (48190-011; 
Invitrogen) and 0.5 mM dNTP. After heating at 65 °C for 5 min, 4 µl of 5 × first-
strand buffer, 2 µl of 100 mM dithiothreitol and 1 µl of RNasin Ribonuclease 
Inhibitor (40 U µl−1, 9PIN211; Promega) were added, followed by incubation at 
37 °C for 2 min and the addition of 200 U of Moloney-murine-leukaemia virus 
reverse transcriptase (28025-013; Invitrogen). Annealing was performed at 37 °C 
for 50 min followed by 15 min at 70 °C. cDNA (0.5 µg) was used as a template 
for PCR amplifications in 5 µl of 10 × PCR buffer (200 mM Tris-HClpH 8.4, 
500 mM KCl, 50 mM MgCl2), 4 µl of 2.5 mM dNTP mix, 2 µl of primers (100 µM), 
0.3 µl of Taq DNA polymerase (10342; Invitrogen), made up to 50 µl with water. 
Amplification was performed for 30 cycles of denaturation for 1 min at 95 °C, 
annealing for 1 min at 64 °C, and extension for 80 s at 74 °C, with final extension 
for 10 min at 74 °C. The products were run on a 1.2% agarose gel and detected by 
staining with ethidium bromide. The primers were designed with the free software 
at http://frodo.wi.mit.edu/. qPCR reactions were performed with 100 ng of DNA 
or cDNA, using the KAPA SYBR FAST qPCR Kit (KK4604; KAPA Biosystems) 
with the following cycling conditions: denaturation at 95 °C for 10 min, followed 
by 40 cycles of 95 °C for 15 s, 60 °C for 1 min, 95 °C for 15 s, 60 °C for 20 s and 
95 °C for 15 s, and a final extension for 10 min at 72 °C. Melting curves between 
65 and 90 °C, 1 °C s−1 transition, were incorporated. All qPCR was performed in 
an AbiPrism 7000 Sequence detection system.
Recombinant lentiviruses. The hairpins sh-Scramble (5´-AGGTAGTGTA-
ATCGCCTTG-3´), sh-BZLF1_1 (5´-GACCAA GCTACC AGAGTCTAT-3´), 
sh-BZLF1_2 (5´-CTGCCTAT CATGTTTCAA CCGC-3´), sh-BPLF1_1 
(5´-ATGTCA G AGT CAGCACCTATG-3´), sh-BPLF1_2 (5´-ACGG CG AATAAT-
ACCGT ATAAC-3´), sh-BPLF1_3 (5´-GCCATCAT CA TCGAGAC AGA-3´) and 
sh-BPLF1_4 (5´-GGCCCAGTT CATCCTCTACAT-3´) were cloned in the AgeI 
and EcoRI sites of the pLKO.1 plasmid46. Recombinant plasmids were co-transfected 
with the packaging plasmids psPAX2 and pMD2.G (Addgene; EPFL) in HEK293T 
cells by precipitation with calcium phosphate, and supernatant containing viral 
particles was collected after 48 h. Virus titres were measured with a QuickTiter 
lentivirus titre kit (Cell Biolabs Inc.).
Screen for EBV deconjugases. The deconjugase activity of an EBV ORF library 
cloned in the pDEST–GST vector was assayed by co-expression with ubiquitin/
UbL–GFP reporters in competent BL21 bacteria as described20. GST fusions 
of the ubiquitin-specific deconjugase USP19 (ref. 47), the ISG15 deconjugase 
USP4 (ref. 48), the NEDD8 deconjugase NEDP1 (ref. 22) and the SUMO-1, 
SUMO-2 and SUMO-3 deconjugase SENP1 (ref. 49) were used as positive con-
trols. Exponentially growing bacteria were induced for 5 h at 30 °C with 0.5 mM 
isopropyl β-d-thiogalactoside and then lysed by sonication in PBS supplemented 
with protease inhibitors. After normalization for GFP content the lysates were 
fractionated by SDS–PAGE and cleavage of the reporters was assessed in western 
blots with anti-S-tag antibody. The intensity of the GFP bands was quantified by 
densitometry and the percentage cleavage was calculated as the ratio between 
the intensity of the free GFP band and the total GFP. Each screen was repeated 
at least twice.
Deconjugase activity assays. GST fusions of BPLF1, a catalytically inactive 
BPLF1C61A mutant, NEDP1 and the catalytic mutant NEDP1C163S were affinity-
purified and protein concentrations were determined. Hydrolysis of the fluoro-
genic substrates ubiquitin-AMC and NEDD8-AMC (Enzo) was assayed at 30 °C 
in 100 µl of buffer (50 mM Tris-Cl pH 7.5, 150 mM NaCl, 2 mM EDTA, 2 mM 
dithiothreitol) containing 50 nM enzyme. Km and kcat were calculated by titrating 
the substrate at concentration ranging between 0 and 20 µM. The enzymatic activ-
ity was blocked by addition of 10 mM NEM. NEDD8 conjugates were purified 
from lysates of HeLa cells transfected with a V5–NEDD8 plasmid by adsorption 
on anti-V5-conjugated Sepharose beads. Equal amounts of beads were incubated 
with 200 nM enzymes for 1 h at 37 °C, and western blots were probed with anti-V5 
antibodies. The enzymatic activity of eukaryotic expressed BPLF1 was assayed by 
labelling lysates of transfected HeLa cells with the ubiquitin-VS and NEDD8-VS 
functional probes (Boston Biochem) as described23. Cell lysate (5 µg) was incu-
bated for 1 h at 37 °C with increasing concentration of the probe. Unmodified 
and ubiquitin/NEDD8-VS crosslinked species were detected in western blots by 
using the anti-Flag antibody. In vivo deneddylase activity was assayed in HeLa 
cells co-transfected with V5–NEDD8 and Flag-tagged BPLF1, NEDP1, BPLF1C61A 
and NEDP1C163S. The transfected cells were harvested after 48 h, and NEDD8 
conjugates were detected in western blots by using the anti-V5 antibody.
Cullin neddylation and co-immunoprecipitation assays. The coding sequences 
of human cullin-1 and cullin-4A were subcloned in the BamH1 and Not1 sites of 
the pcDNA4/Myc vector (Invitrogen). Cullin deneddylation was assayed in HeLa 
cells co-transfected with the Myc-tagged cullins, V5–NEDD8 and Flag–BPLF1, 
Flag–BPLF1C61A or Flag–NEDP1. Cell lysates prepared 48 h after transfection 
were fractionated by SDS–PAGE, and western blots were probed sequentially 
with the anti-Myc and V5 antibodies. For co-immunoprecipitation, aliquots of 
the cell lysates were incubated either for 1 h with the anti-Myc antibody followed 
by Protein-G-coupled Sepharose beads (GE Healthcare) or for 2 h with anti-Flag 
agarose affinity gel (A-2220; Sigma) followed by elution with a 3 × Flag pep-
tide (F-4799; Sigma). Western blots were probed sequentially with the anti-Myc 
and anti-Flag antibodies. Interaction with endogenous cullins was assayed by 
immunoprecipitation of cell lysates of HeLa cells transfected with empty vector, 
Flag–BPLF1 and Flag–BPLF1C61A with anti-Flag and anti-Cull4A antibodies.
Immunofluorescence and cell cycle analysis. The subcellular localization of 
Flag–BPLF1 and Flag–BPLF1C61A was investigated by immunofluorescence. 
HeLa cells were grown on coverslips and transfected with the jetPEI Kit (Polyplus 
Transfection). After 48 h the monolayers were fixed with 4% paraformaldehyde 
and permeabilized for 20 min with 0.5% v/v Triton X-100 in PBS. Staining with the 
anti-Flag antibody (didilution 1:5,000 in PBS containing 0.5% BSA) was performed 
for 2 h at room temperature followed by incubation for 1 h with tetramethylrhod-
amine β-isothiocyanate-conjugated anti-mouse immunoglobulin antibodies (1:200 
dilution; R0270; Dako). Cytoskeletal actin was stained with FITC-labelled phal-
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loidin (1:100 dilution; P-5252; Sigma). The slides were mounted with Vectashield 
containing DAPI (H-1200; Vector Laboratories) and images were captured with 
a Leica DM RXA fluorescent microscope and analysed with the Improvision 
OpenLab 3.1.4 software (http://www.improvision.com). Nuclear size was meas-
ured with the ImageJ software (http://rsbweb.nih.gov). For staining with PI, the 
cells were fixed for 1 h in cold 70% ethanol and stained for 45 min in ice-cold stain-
ing solution (50 mg ml−1 PI, 25 mg ml−1 RNase A, 1 mg ml−1 sodium citrate, 0.3% 
Nonidet P40). DNA content was measured by fluorescence-activated cell sorting 
(FACS) with a FACSCalibur (Becton Dickinson) and analysed with CellQuestPro 
software. Where indicated, the cells were co-transfected with 2 µg of the BPLF1 
plasmid and increasing amounts of either the HA–ubiquitin or the V5–NEDD8 
plasmids for 48 h before being stained with PI.
Induction of the EBV productive cycle and quantification of viral DNA. The 
productive virus cycle was induced in the Akata Bx-1 cell line that carries a recom-
binant EBV in which the thymidine kinase gene is replaced by a cytomegalovirus 
(CMV) immediate-early promoter-driven GFP, by incubating cell pellets for 1 h 
at 37 °C with polyclonal rabbit anti-human IgG32. EBV DNA content was assayed 
by qPCR with probes specific for unique regions in the genes encoding BZLF1 
and EBNA1 and the KAPA SYBR FAST qPCR Kit (KK4604; KAPA Biosystems). 
Where indicated, EBV DNA replication was inhibited by the addition of 50 µM 
Foscarnet, a herpesvirus DNA polymerase inhibitor50. Akata-Bx1 cells were 
infected with recombinant lentiviruses for 72 h at a multiplicity of infection of 
2.55 × 1010 in the presence of 8 mg ml−1 Polybrene (AL-118; Sigma). Where indi-
cated, cells infected for 24 h were treated with anti-human IgG antibody for 48 h 
before FACS and western blot analysis. A human CDT1 expression plasmid was 
purchased from OriGene Technologies (SC122393). Expression was assayed in 
cells transfected with the Cell Line Nucleofector Kit V (AMAXA; Lonza Group) 
using a specific antibody.
46. Moffat, J. et al. A lentiviral RNAi library for human and mouse genes applied to an 
arrayed viral high-content screen. Cell 124, 1283–1298 (2006).
47. Hassink, G. C. et al. The ER-resident ubiquitin-specific protease 19 participates in the 
UPR and rescues ERAD substrates. EMBO Rep. 10, 755–761 (2009).
48. Zhao, B., Schlesiger, C., Masucci, M. G. & Lindsten, K. The ubiquitin specific pro-
tease 4 (Usp4) is a new player in the Wnt signalling pathway. J. Cell. Mol. Med. 13, 
1886–1895 (2009).
49. Duda, D. M. et al. Structure of a SUMO-binding-motif mimic bound to Smt3p–
Ubc9p: conservation of a non-covalent ubiquitin-like protein-E2 complex as a plat-
form for selective interactions within a SUMO pathway. J. Mol. Biol. 369, 619–630 
(2007).
50. Yao, G. Q., Grill, S., Egan, W. & Cheng, Y. C. Potent inhibition of Epstein–Barr virus by 
phosphorothioate oligodeoxynucleotides without sequence specification. Antimicrob. 
Agents Chemother. 37, 1420–1425 (1993).
nature cell biology
© 2010 Macmillan Publishers Limited.  All rights reserved. 
 
s u p p l e m e n ta ry  i n f o r m at i o n
www.nature.com/naturecellbiology 1
DOI: 10.1038/ncb2035
Figure S1 Western blot analysis of bacteria co-expression assays where 
GST-BPLF1 was testes for cleavage of the Ub- and UbL-GFP reporters 
alongside the empty GST vector and the appropriate positive controls 
(USP19, NEDP1, USP4 and SENP1). Cleavage of the reporter is visualized 
by the appearance of a free GFP band (GFP) detected by antibodies to the 
C-terminal S-tag.
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Figure S2 BPLF1 cleaves ubiquitin conjugates. HA-ubiquitin was expressed 
in HeLa cells and conjugates were captured on anti-HA conjugated 
sepharose beads. Equal amounts of beads were mixed with 200 nM of 
purified GST- or GST-BPLF1 and the reaction was run for 1h at 37°C. 
Ubiquitin conjugates were visualized in Western blots probed with the HA 
antibody. Immunoglobulin heavy and light chains are indicated by asterisks.
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Figure S3 A catalytically active BPLF1 selectively induces the accumulation of 
CRL substrates. The expression levels of Rb (MDM2 substrate), p53 (MDM2 
substrate), CycB (APC/C substrate), p27 and p21 (CRL1Skp2 substrates) 
were assayed in HeLa cells 48h after transfection with the wild type BPLF1, 
the catalytic mutant BPLF1C61A or a control empty vector. Expression of the 
catalytically active BPLF1 was associated with accumulation of CRL substrates 
p21 and p27 while the expression levels of Rb, p53 and CycB were not affected. 
The result of one representative experiments out of three are shown in the figure. 
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Figure S4 Time kinetics of EBV gene expressed in untreated and anti-IgG 
treated Akata-Bx1. Total RNA were extracted at the indicate time and cDNA 
were synthesized as described in materials and methods. Quantitative PCR 
were preformed on cDNA templates with the specific primers, and GAPDH 
was used as standard control for the normalization. The products were run in 
1.5% agarose gel and the fold increase is plotted on the graphic.
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Figure S5 Characterization of shRNA lentiviruses. The empty pLKO.1 vector 
and recombinant plasmids expressing a scrambled shRNA or shRNAs 
specific for the EBV BZLF1 and BPLF1 genes were co-transfected in HeLa 
cells together with plasmids expressing BZLF1 or Flag-BPLF1 at 9:1 molar 
ratio and expression of the viral proteins was assayed after 72 h in Western 
blots probed with the anti-BZLF1 or anti-Flag antibodies. The shBZ1-1 and 
shBP1-2 and -4 hairpins that induced >90% silencing of the target mRNAs 
were used for production of recombinant lentiviruses.
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Figure S6 Full scans for figures 1d and 1e. The rectangles correspond to the crops
Scans for figures 1d and 1e. The rectangles correspond to the crops.  
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Figure S6 continued Full scans for figures 2a and 2b. The rectangles correspond to the crops
Scans for figures 2a and 2b. The rectangles correspond to the crops.  
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Figure S6 continued Full scans for figure 2d. The rectangles correspond to the crops
Figure S6 Mr(K) 
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Scans for figures 2c and 5e.  
The rectangles correspond to the crops.  
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Figure S6 continued Full scans for figures 2c and 5e. The rectangles correspond to the crops
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Scans for figures 6a, 7a and 7c. The rectangles correspond to the crops.  
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Figure S6 continued Full scans for figure 6a, 7a and 7c. The rectangles correspond to the crops
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Scans for figures 8a and 8b. The rectangles correspond to the crops.  
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